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“When a thing is new, people say:  
‘It is not true.’  
Later, when its truth becomes obvious, they say:  
‘It is not important.’  
Finally, when its importance cannot be denied, they say:  
‘Anyway, it is not new.” 
 
William James 
 
 
 ABSTRACT 
Lithium is an alkali metal commonly used for treating mood disorders. A more common 
source of lithium exposure worldwide is drinking water, including bottled water, although 
few measurements have been performed. Based on clinical and experimental studies, lithium 
at therapeutic doses may impair fetal growth and development. Also, lithium may impair the 
thyroid and calcium homeostases in lithium-treated patients, but data on people exposed to 
lithium through drinking water are very limited. 
The overall aim of this PhD thesis was to elucidate the potential impact of the exposure to 
lithium via drinking water during pregnancy on maternal and fetal health. Specifically, we 
aimed at elucidating the transfer of lithium through the placenta and mammary gland and the 
potential impact of lithium exposure during pregnancy on fetal size and maternal thyroid and 
calcium homeostases.  
By analyzing lithium in banked samples from a small mother-child cohort (n=11) recruited in 
1996 in San Antonio de los Cobres, an area with elevated lithium in the drinking water in 
northern Argentina, we evidenced a marked transfer of lithium through the placenta. The 
lithium concentration in cord blood was at least as high as in maternal blood and both were 
highly correlated (rs=0.82). In line with this, the lithium concentration in the newborns’ first 
urine in life was highly elevated. The urinary lithium concentration of the infants decreased 
during exclusive breastfeeding, consistent with the observed lower transfer of lithium through 
the mammary gland into breast milk. 
To clarify the potential impact of lithium exposure on fetal and birth size and underlying 
mechanisms, we recruited a larger mother-child cohort from October 2012 to December 2013 
(n=194, participation rate 88%) covering most of the Andean part of the Province of Salta in 
northern Argentina. The lithium concentrations in the drinking water were about 700 μg/L in 
the main village of San Antonio de los Cobres and from 5.0 to 242 μg/L in the surrounding 
nine villages. The selected biomarker of lithium exposure was blood lithium (overall median 
25 μg/L) which showed a wide range of distribution (1.9-145). Lithium concentration in 
blood correlated very well with that in plasma (rs=0.99) and urine (rs=0.84), and, to a lesser 
extent, with that in water (rs=0.40). 
In multivariable-adjusted linear regression models, we observed that maternal blood lithium 
concentrations were inversely associated with fetal size. A 25 μg/L increment in the blood 
lithium concentrations was associated with a statistically significant decrease of 0.5 cm in 
birth length. Newborns to mothers in the highest tertile of lithium exposure (median blood 
lithium 47 μg/L) were on average 0.8 cm shorter than those in the lowest tertile of exposure 
(median blood lithium 11 μg/L). 
Based on multivariable-adjusted quantile regression across pregnancy, blood lithium 
concentrations were positively associated with thyrotropin (TSH) and inversely associated 
with free (fT3) and total triiodothyronine (T3) and with transthyretine (TTR).  
Using multivariable-adjusted linear mixed-effects models across pregnancy, we observed 
blood lithium to be inversely associated with plasma vitamin D3 concentrations and with 
urinary calcium and magnesium, and positively associated with serum magnesium. A 25 μg/L 
 increment in the blood lithium concentrations was associated with an odds ratio of 3.5 for 
having vitamin D3 concentrations <50 nmol/L, and an odds ratio of 4.6 for having vitamin D3 
concentrations <30 nmol/L, an association independent of season of sampling. 
Taken together, the results of this thesis provide evidence of a marked transfer of lithium 
through the placenta and a consequent lithium exposure to the fetus. This elevated fetal 
exposure seemed to impair the fetal size. Findings of a potential lithium-related impaired 
homeostasis of the thyroid and calcium systems in the mother during pregnancy might be 
underlying mechanisms of action of lithium. Further studies are indeed warranted. 
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1 INTRODUCTION 
The focus of this thesis is the potential impact of maternal and fetal exposure to lithium from 
drinking water on fetal growth and maternal thyroid and calcium homeostases during 
pregnancy. Although lithium’s pharmaceutical use as therapy for bipolar disease has been 
extensively studied (Grandjean and Aubry 2009b), very little is yet known concerning 
environmental exposure to lithium from drinking water and food, and in particular, the 
potential adverse health effects of such exposure on maternal and fetal health. It is 
particularly important to assess the exposure and potential health effects in early life since 
this is considered the most critical window of exposure for many contaminants (Barouki et al. 
2012) and effects at this stage in life may persist or aggravate in adulthood (Barker et al. 
2013; Barker et al. 2002). Besides reviewing the methods used and the results found, the 
present summary also focuses on certain methodological problems encountered as well as in 
more depth description of the potential involved mechanisms of lithium toxicity. 
 
2 BACKGROUND 
2.1 LITHIUM 
2.1.1 Chemistry and use of lithium 
The alkali metal lithium (chemical symbol Li, atomic number 3, atomic weight 6.9) is the 27th 
most abundant element on earth and is naturally found at varying concentrations in rocks, soil 
and water (Oruch et al. 2014). Naturally-occurring lithium is composed of two stable 
isotopes, 6Li and 7Li, the latter being the most abundant (92.5%) (Oruch et al. 2014). Today, 
lithium is primarily mined for use in the manufacturing of ceramics and glass (29%), batteries 
(27%) and, to a lesser extent, medicines (2%) (Figure 1). The largest lithium-producing 
countries are Australia and Chile, followed by China and Argentina (Jaskula 2015). 
 
Figure 1. Uses of lithium. Data obtained from the U.S. Geological Survey (Jaskula 2012). 
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2.1.2 Lithium therapy 
Lithium has been used in the therapy for mood disorders, particularly bipolar disease, for 
more than 50 years. Lithium efficacy is largely dose dependent, although there is a clear 
inter-individual variation in the response (Grandjean and Aubry 2009a). The daily dose of 
lithium, prescribed for mood disorders, ranges between 375 and 1,300 mg. Serum or plasma 
concentrations of lithium need to be regularly monitored in the patients. The therapeutic 
window of lithium concentration in plasma is usually between 0.8 and 1.2 mmol/L (i.e. 
5,550–8,330 μg/L) (Grandjean and Aubry 2009a; Malhi et al. 2011).  
 
Several side effects are reported in patients undergoing lithium therapy, particularly, 
increased risk of kidney failure, hypothyroidism, hyperparathyroidism and weight gain 
(McKnight et al. 2012). During pregnancy, lithium therapy has been associated with 
increased risk for miscarriages and prematurity, as well as malformations, hypothyroidism 
and goiter in the offspring (Cohen et al. 1994; Diav-Citrin et al. 2014; Gentile 2012; 
Grandjean and Aubry 2009c; Oyebode et al. 2012). 
 
2.1.3 Lithium in the environment 
2.1.3.1 Lithium in drinking water 
A source of general environmental exposure to lithium is drinking water, although there are 
very few studies on both the exposure and the potential health consequences. Lithium 
concentrations in drinking water have been reported to vary from <1 to 219 µg/L in Texas 
(Schrauzer and Shrestha 1990), Japan (Ohgami et al. 2009), Italy (Pompili et al. 2015), 
Greece (Giotakos et al. 2015) and England (Kabacs et al. 2011); while in a few regions in 
Austria (Kapusta et al. 2011), northern Chile (Zaldivar 1980), southern Bolivia (Ormachea 
Munoz et al. 2013) and northern Argentina (Concha et al. 2010), the concentrations exceed 
1,000 µg/L (Figure 2). However, the lithium concentration in drinking water sources is still 
unknown in most countries. 
Several ecological studies have investigated the relationship between lithium concentrations 
in public drinking water and suicide rates (Bluml et al. 2013; Giotakos et al. 2013; Giotakos 
et al. 2015; Helbich et al. 2012, 2015; Ishii et al. 2015; Kabacs et al. 2011; Kapusta et al. 
2011; Ohgami et al. 2009; Pompili et al. 2015; Schrauzer and Shrestha 1990; Sugawara et al. 
2013). However, the results are inconsistent and due to the nature of these studies, many 
potential confounding factors are not considered at the individual level. It should be noted 
that the lithium concentrations in these studies are low (<1-219 µg/L, most <20 µg/L), and 
lower than those in the study area of the present thesis. 
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Figure 2. Available data on lithium concentrations in drinking water worldwide. World map modified from: 
www.worldatlas.com. References of the lithium concentrations in the different countries are provided in the text. 
Certain brands of bottled water also contain high concentrations of lithium, e.g. up to 5,000 
µg/L in products from Germany and Yugoslavia, about 5,500 µg/L in a product from France 
and almost 10,000 µg/L in one from Slovakia (Allen et al. 1989; Krachler and Shotyk 2009; 
Reimann 2010). At the same time, lithium is usually not analyzed in the regular control of 
drinking water quality and only Russia and Ukraine have set limits for lithium in drinking 
water (<30 µg/L) (Reimann 2010).  
2.1.3.2 Lithium in food 
Environmental exposure to lithium could also occur via food, although the concentrations are 
usually very low. Grains and vegetables, in particular spinach, appear to contain the highest 
concentrations of lithium (0.5-4.6 µg/g), while dairy products contain about 0.50 µg/g and 
meat about 0.012 µg/g (Ammari et al. 2011; Schrauzer 2002). One brand of low-sodium salt, 
extracted from lithium-rich salt flats, was found to contain 44 µg/g (our unpublished data). 
Thus, consumption of 10 g of such salt a day would result in an intake of 440 µg of lithium. 
The lithium intake in the U.S. has been estimated to 9-44 µg/kg/day (Schrauzer 2002). The 
same author has proposed that lithium is essential for humans but the evidence for this is 
scarce and no mechanisms have been established. 
Other routes of exposure such as inhalation or dermal absorption seem to contribute very 
little to the lithium concentrations in serum (Moore 1995). 
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2.1.4 Toxicokinetics 
After oral ingestion, lithium is rapidly and completely absorbed from the gastrointestinal tract 
by passive diffusion through pores in the small intestinal membrane and, to a much lesser 
extent, actively transported in exchange for sodium (Bauer et al. 2006). Once in the body, 
lithium is widely distributed in the interstitial fluid. Lithium is not subject to metabolic 
transformation and 95% is excreted through the kidneys as a free ion, while 1% can be found 
in the feces and 4% in sweat (Grandjean and Aubry 2009a; Morgan et al. 2003). The 
elimination half-life of lithium in plasma varies between 16 and 30 hours in patients with 
adequate kidney function. However, it increases in lithium-treated patients with time of 
medication to up to 60 hours in patients treated for more than 1 year (Goodnick et al. 1981). 
The kinetics of low-dose lithium from environmental sources is largely unknown. 
Lithium crosses the blood-brain barrier and its concentration in the human brain is 50-80% of 
that found in serum in lithium-treated patients (Soares et al. 2000). Lithium accumulates 
mainly in bone (half-life several months), but also in the kidney, thyroid, brain (~10 days) 
and bile (>24 hours) (Birch and Hullin 1972; Grandjean and Aubry 2009a; Spirtes 1976).  
 
2.1.4.1 Toxicokinetics during pregnancy and lactation 
In patients on lithium therapy, lithium crosses the placenta, as indicated by the high 
concentration of lithium in the amniotic fluid [about 10,000 µg/L; (MacKay et al. 1976)] as 
well as by the similar lithium concentrations in plasma of women and their newborns 
(Newport et al. 2005; Schou and Amdisen 1975; Sykes et al. 1976). There are no similar 
studies concerning women environmentally exposed to lithium. 
It has been suggested that lithium passes freely into breast milk (Moore 1995). However, 
there seems to be a wide inter-individual variation in the transfer of lithium through the 
mammary gland in lithium-treated patients; and the lithium concentration in breast milk has 
been reported to constitute anything from 10 to 80% of that found in maternal serum 
(Grandjean and Aubry 2009c; Schou and Amdisen 1973; Viguera et al. 2007). 
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2.2 HEALTH EFFECTS OF LITHIUM 
2.2.1 Fetal size and lithium  
The embryonic and fetal development are periods that require careful regulation of processes 
involving cell proliferation, formation and functionality of cell lineages and interaction 
between cell types (Harding and Bocking 2001). The whole embryonic and fetal development 
takes about 280 days (40 weeks). The first days involve fertilization and blastocyst formation, 
followed by implantation and gastrulation, i.e. formation of the three germ layers ectoderm, 
mesoderm, and endoderm (Figure 3). Then, the process of organogenesis starts (week 3-8), 
which is the period with the highest risk for malformations (Langman and Sadler 2000). The 
final fetal stage is characterized by cell proliferation and growth (week 9-40). 
 
 
Figure 3. Stages of embryonic and fetal development (the pink color indicates stages with the highest risk for 
malformations and mortality and yellow color indicates lower risk). Modified from (Moore and Persaud 2003). 
 
Lithium is classified as teratogenic (category D) by the U.S Food and Drug Administration 
and it is recommended not to use lithium in early pregnancy (Grandjean and Aubry 2009c). A 
few human studies and several experimental studies (Morgan et al. 2003), particularly with 
mice and rats, have investigated the potential teratogenicity of lithium and its impact on fetal 
growth and development, but their results are inconsistent (Table 1).  
 
 
 6 
Table 1. Summary of studies on lithium exposure during pregnancy and fetal or post-natal size. 
 
Study Sample size Li-exposure levels Results of interest in the Li-exposed 
group 
Human studies     
Diav-Citrin et al. 2014 Prospective  
observational  
Bipolar Li therapy n=183 
Bipolar no Li therapy n=72 
Control n=748 
N/A Lower birth weight (40g., borderline 
significant), higher proportion of 
preterm births and miscarriages. 
Jacobson et al. 1992 Prospective  
observational  
Patients Li therapy n=138 
Control n=148 
N/A Higher birth weight (94 g, p=0.025). 
Newport et al. 2005 Prospective  
observational  
Bipolar Li therapy n=12 
Control n=12 
300-1800 mg/day Lower Apgar score, longer hospital 
stay, higher proportion of low birth 
weight, preterm births and newborns 
with complications. 
 
 
Experimental studies in mice    
Chernoff and Kavlock. 1982 Mice Li-exposed n=25 
Control n=30 
400 mg/kg/day 
orally 
No effect on pup weight. Reduced 
litter size. 
Giles and Bannigan. 1993 Mice Li-exposed n=8-20 
Control n=8-20 
200, 300, 350, 400 
mg/kg injection 
No effect on embryo or fetal weight. 
Laborde and Pauken. 1995 Mice Li-exposed n= N/A 
Control n= N/A 
0.5, 1, 1.5, 2, 2.5 
mg/mL water orally 
Reduced fetal weight and crown-rump  
length. No dose-response was 
reported. 
Matsumoto et a. 1974 Mice Li-exposed n= N/A 
Control n= N/A 
400 mg/kg orally  Reduced fetal weight and ossification 
centers in digits of hindlimbs and tail 
vertebrae. 
Messiha 1986 Mice Li-exposed n=5 
Control n=5 
Drinking water with 
~7mg/L ad libitum 
Lower liver and kidney weight in 
females and lower spleen weight in 
females and males. 
Messiha 1989 Mice Li- and Cs exposed n=3 
Control n=3 
Drinking water with 
~7mg/L ad libitum 
Effects were only seen in the Li-
treated group. Lower brain weight in 
females and males, lower kidney 
weight in females, increased liver and 
spleen weight during weaning. 
Messiha 1993 Mice Li-exposed n=5 
Control n=5 
Drinking water with 
~7mg/L ad libitum 
Lower post-natal total weight as well 
as brain (males and females), kidney 
(females) and testis (males) weight. 
Mroczka et al. 1983 Mice Li-exposed n=252 
Control n=283 
70, 140, 210, 350, 700 
and 1400 mg/day 
orally 
Lower post-natal brain, liver, kidney 
and heart weight, higher post-natal 
mortality, more frequently in the 
females.  No dose-response was 
reported. 
Seidenberg et a. 1986 Mice Li-exposed n=28 
Control n=28 
400 mg/kg/day 
orally 
No effects on post-natal pup weight. 
Li: lithium; Cs: cesium; GD: gestational day; G: group; N/A: not available.  
  7 
Table 1 (cont). Summary of studies on lithium exposure during pregnancy and fetal or post-natal size. 
 
 
 
Study Sample size Li-exposure levels Results of interest in the Li-exposed 
group 
Experimental studies in rats    
Christensen et al. 1982 Rats Li-exposed n=20 
Control n=20 
280 and 420 mg/kg 
orally 
No effects on pup birth weight. 
Fritz. 1988 Rats Li-exposed n=16, 19, 14 
Control n=20 
100 mg/kg/day at  
GD: 6-10, 11-15, 16-
20, orally in food 
Reduced body weight in all Li-treated  
groups. 
Glockner et al. 1989 Rats Li-exposed n=30 
Control n=20 
140 mg/L in water 
orally 
No effects on pup body weight. 
Gralla and McIlhenny. 1972 Rats Li-exposed n=20 
Control n=20 
4.7, 14.2, 28.4 
mg/kg/day orally 
Reduced post-natal pup body weight at 
28.4 mg/kg/day. 
Hsu and Rider. 1978 Rats Li-exposed n=13 
Control n=10 
7mg/kg orally Reduced body weight at weaning. 
Ibrahim and Canolty. 1990 Rats Li-exposed n=13 
Control n=11 
188 mg/kg food , 
orally 
Reduced birth weight in Li-treated 
group. 
Reduced growth at weaning in the Li-
treated post-natally. 
Johansen and Ulrich. 1969 Rats Li-exposed n=22 
Control n=13 
G1: 6.9 mg/kg/day 
G3: 20.8 mg/kg/day 
orally 
Retarded post-natal growth in G3 group. 
Marathe and Thomas. 1986 Rats Li-exposed n=23 
Control n=20 
50 and 100 
mg/kg/day 
orally 
Reduced fetal weight at 100 mg/kg/day. 
Rider and Hsu. 1976 Rats Li-exposed n=13 
Control n=10 
140 mg/kg/day 
orally 
Reduced liver weight and pup weight at 
weaning. 
Rider et al. 1978 Rats Li-exposed n=12 
Control n=11 
105 mg/L in water 
orally 
Reduced birth weight. 
Reduced spleen weight in females. 
Sechzer et al. 1986 Rats Natural Li salts n=15 
Li-6 n=15 
Li-7 n=13 
Control n=16 
13,9 mg/kg/day 
orally 
Lower birth weight in all Li-treated  
groups. 
Sharma and Rawat. 1986 Rats Li-exposed n=77 
Control n=100 
7 mg/kg 
intragastrically 
for 10 days 
Reduced fetal body weight and size 
Texeira et al. 1995 Rats Li-exposed n=44 
Control n=59 
70 mg/kg orally Reduced pup weight at weaning. 
Trautner et al. 1958 Rats Li-exposed n=25 
Control n=30 
140 mg/kg/day  
orally 
Slower post-natal growth. 
Experimental studies in monkeys    
Gralla and McIlhenny. 1972 Monkeys Li-exposed n=6 
Control n=5 
4.7 mg/kg/day orally Reduced fetal and post-natal body 
weight. 
In vitro     
Klug et al. 1992 Rat embryos 
  
0, 50, 100, 150, 200 
mg/L 
Crown-rump length reduced with  
exposures >150 mg/L  
Li: lithium; Cs: cesium; GD: gestational day; G: group; N/A: not available. 
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Two human studies have found a higher proportion of low birth weight babies born to 
mothers undergoing lithium treatment, compared to a control group (Diav-Citrin et al. 2014; 
Newport et al. 2005), while a third study found increased birth weight in the newborns to 
mothers in the treated group (Jacobson et al. 1992). In the latter study, however, no 
association was found between birth weight and the lithium dose (range 50-2400 mg/day). 
At different lithium doses (7-400 mg/kg/day, Table 1), several experimental studies have 
reported a reduced birth weight in mice (Laborde and Pauken 1995; Matsumoto et al. 1974) 
and rats (Ibrahim and Canolty 1990; Marathe and Thomas 1986; Rider et al. 1978; Sechzer et 
al. 1986; Sharma and Rawat 1986), as well as reduced post-natal organ and body weight in 
mice (Messiha 1986, 1993, 1989; Mroczka et al. 1983) and rats (Fritz 1988; Gralla and 
McIlhenny 1972; Hsu and Rider 1978; Ibrahim and Canolty 1990; Johansen and Ulrich 1969; 
Rider and Hsu 1976; Rider et al. 1978; Texeira et al. 1995; Trautner et al. 1958). All these 
studies used doses representing those of lithium therapy. An in vitro study on cells from rat 
embryos found a decreased crown-rump length with lithium doses >150 mg/L (Klug et al. 
1992). 
On the contrary, a few studies on mice and rats, using doses of 140 mg/L in the drinking 
water or >200 mg/kg/day (orally or by injection), have found no effects in birth or post-natal 
weight (Chernoff and Kavlock 1982; Christensen et al. 1982; Giles and Bannigan 1993; 
Glockner et al. 1989; Seidenberg et al. 1986).  
 
2.2.2 Thyroid function and lithium  
A brief overview of the normal thyroid function is provided in Figure 4. The thyroid gland 
releases thyroxine (T4) and triiodothyronine (T3) which are in charge of controlling several 
functions in the body, e.g. heart rate, body weight and body temperature (Guyton and Hall 
2006). During pregnancy, thyroid hormones are essential for normal fetal growth and 
development (Polak 2014). Thyrotropin (TSH) production increases in early pregnancy due 
to the influence of the human chorionic gonadotropin hormone (hCG) released by the 
hypothalamus, which has a TSH-like activity. There is also an increase in the thyroxine-
binding protein (TBG) production, in the transplacental transfer of thyroid hormones and in 
the renal iodine excretion (Kennedy et al. 2010). Due to the increase in the TBG production, 
T4 and T3 decrease, particularly in early pregnancy (Lockitch 1993). 
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Disruption of the thyroid function is a well-known side effect of lithium therapy (Grandjean 
and Aubry 2009c). Disturbances of the thyroid function during pregnancy may lead to 
gestational hypertension, placental abruption, pre-term delivery and fetal loss (Allan et al. 
2000; Casey 2005) as well as lower birth weight, congenital hypothyroidism and impaired 
neurological function (Chen et al. 2014; Haddow et al. 1999; Zimmermann 2012). 
  
Most studies investigating thyroid function in relation to lithium exposure are based on 
patients undergoing lithium therapy. A meta-analysis including case-control studies showed a 
6-fold increased risk (95% CI 2.72; 13.4) of developing clinical hypothyroidism in patients 
on lithium therapy compared with controls (McKnight et al. 2012). A randomized double-
blind placebo-controlled clinical trial showed a higher mean TSH concentration in the 
lithium-treated group (Frye et al. 2009) and a prospective double-blind clinical trial showed a 
reduction in thyroid morbidity when decreasing the lithium dose to a serum lithium 
concentration <0.79 mmol/L (5.5 mg/L) (Coppen et al. 1983).  
A recent study including women exposed to lithium through drinking water, the only one 
with environmental exposure, found a positive association of urinary lithium concentrations 
with TSH, as well as an inverse association with free T4 (fT4) (Broberg et al. 2011). 
Figure 4. Normal thyroid function. TRH: 
thyrotropin-releasing hormone, TSH:  thyrotropin or 
thyroid-stimulating hormone, T4: thyroxine, T3: 
triiodothyronine, Tg: thyroglobulin, TPO: 
thyroperoxidase, TBG: thyroxine-binding protein, 
TTR: prealbumin or transthyretin, 5’D: deiodinases I 
and II, THr: thyroid hormone receptor. Gray arrows 
represent changes in the thyroid function during 
pregnancy. 
Stimulation of the hypothalamus induces the 
production of TRH which in turn stimulates the 
production of TSH. The latter has several functions. 
Particularly, TSH increases the Tg proteolysis, the 
iodine uptake by the thyroid gland, the iodination of 
T4, and the size and production of the thyroid 
follicles. After T4 and T3 are released to the blood 
stream, they bind partially to TBG, albumin and 
TTR. Increment in TSH inhibits the TRH 
production, and increment in T4 and T3 inhibits 
TSH and TRH (Guyton and Hall 2006).  
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2.2.3 Calcium homeostasis and lithium  
The calcium homeostasis is closely related to that of parathyroid hormone (PTH), vitamin D, 
magnesium and phosphorus. A summarized scheme of the calcium-phosphorus-magnesium-
vitamin D homeostatic systems is shown in Figure 5. Although much is known about these 
homeostatic systems and their interrelation, everything is not yet fully understood.  
 
 
 
Figure 5. Schematic overview of the calcium-phosphorus-magnesium-vitamin D homeostatic systems.  
DBP: vitamin D binding protein; Ca: calcium, P: phosphorus, Mg: magnesium, PTH: parathyroid hormone, 
25(OH)-D3: 25-hydroxyvitamin D3, 1,25(OH)2-D: 1,25-dihydroxyvitamin D, 1-α-OHase: 1-alpha-hydroxylase, 
CYP24A1: 24-hydroxylase, 24,25(OH)2D: 24,25 dihydroxyvitamin D, FGF23: fibroblast growth factor 23, 
UVB: ultraviolet B. Dashed lines represent vitamin D catabolic pathways.  
 
A: Vitamin D is mainly produced from the conversion of 7-dehydrocholesterol to previtamin D3 in the skin by 
UVB radiation. Once in the body, vitamin D3 is converted to 25(OH)-D3 and then to 1,25(OH)2-D (the active 
form). CYP24A1 catabolizes both vitamin D forms to be excreted as 24,25(OH)2D or as inactive calcitroic acid 
through the kidneys. 
 
B: A decrease in the circulating Ca concentrations induces the production of PTH in the parathyroid gland, 
which releases Ca and P from the bone to the blood and decreases the renal Ca and P excretion. Decreased Ca 
concentrations will also increase the intestinal absorption of Mg, P and Ca directly in the small intestine or by 
stimulating the production of 1,25(OH)2-D. 
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Approximately 99% of the total amount of calcium in the body is stored in the bones and the 
remaining 1% is located in soft tissue and the extracellular fluid, including blood (Guyton and 
Hall 2006). Due to calcium’s critical role in many physiological processes, the calcium 
concentration in serum is strictly regulated. Similar to calcium, most phosphorus (85%) is 
stored in the bones, while 14-15% is located intracellularly and 1% in the extracellular 
compartment. Both calcium and phosphorus levels are controlled by the parathyroid 
hormone, which is produced in the parathyroid gland. Magnesium is the second most 
abundant essential element within the cells and only 1% of it is found extracellularly, while 
60%, 20% and 19% is found in bone, skeletal muscle and other tissues, respectively (Burtis 
and Ashwood 1999).  
Vitamin D is also an important component of this homeostatic system. Sources of vitamin D 
include UVB radiation, which converts 7-dehydrocholesterol to previtamin D3 in the skin, as 
well as food (Brannon and Picciano 2011). Once in the body, vitamin D goes through a series 
of enzymatic reactions to finally be converted to 1,25-dihydroxyvitamin D, the active form 
(Figure 5). 
During pregnancy, the homeostasis of these systems is critical for ensuring normal fetal 
growth and development. Particularly, disturbances in the homeostasis of vitamin D and in 
the parathyroid system are associated with preeclampsia, infectious diseases as well as 
impaired fetal development (Brannon and Picciano 2011; Karras et al. 2014).  
Impairment of the calcium homeostasis, diagnosed often as hyperparathyroidism, is another 
known side effect of lithium therapy (Grandjean and Aubry 2009c). A systematic review of 
case-control studies with patients undergoing lithium therapy found a significant increase in 
serum calcium and in the concentrations of parathyroid hormone (McKnight et al. 2012). 
Three studies, based on patients on lithium therapy, have investigated the potential impact of 
lithium on vitamin D and reported a decrease in the 25-hydroxyvitamin D3 concentrations in 
the lithium-treated group, compared to controls (Haden et al. 1997; Oliveira et al. 2014; van 
Melick et al. 2014). None of these studies included pregnant women. 
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3 AIMS  
The overriding aim of our ongoing research concerning environmental lithium exposure was 
to clarify the potential impact of exposure to lithium via drinking water during pregnancy on 
maternal and fetal health. 
Specifically, this PhD thesis aimed at elucidating: 
 The transfer of lithium from drinking water through the placenta and the mammary 
gland. 
 The potential impact of exposure to lithium during pregnancy on fetal size.  
 The association between lithium exposure and maternal thyroid function during 
pregnancy. 
 The association between lithium exposure and maternal calcium homeostasis during 
pregnancy. 
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4 MATERIALS AND METHODS WITH DISCUSSION 
This section summarizes the materials and methods used in this thesis. For further details, the 
reader is referred to the individual papers (Papers I-IV). A broader description of the study 
area, recruitment and sample collection, as well as a discussion of the exposure assessment, is 
also provided in this section. 
4.1 STUDY AREA 
The present thesis was performed in the Puna region, on the eastern side of the Andes, in the 
province of Salta in northern Argentina. The study site included the whole Los Andes 
Department and part of La Poma and Rosario de Lerma Departments (Figure 6). The study 
area is located at 3,180-4,070 meters above the sea level, latitude from -23.31 to -24.35, and 
longitude from -65.51 to -67.23. The total area is about 32,000 km2 with a population density 
of only 0.2 inhabitants/km2. By December 31st 2013, the total population of this area was 
8,135 inhabitants, out of whom 5,893 lived in the main village of San Antonio de los Cobres 
(Figure 7), and the rest in the nine surrounding villages: Santa Rosa de los Pastos Grandes, 
Tolar Grande, Salar de Pocitos, Olacapato, Cobres, Las Cuevas, El Toro, El Palomar and 
Esquina de Guardia (Table 2).  
 
Figure 6. Map of the study area. Topographic map of Salta obtained from: NASA/JPL/NIMA; World map 
modified from Dexxter via Wikimedia Commons [CC BY 3.0 (http://creativecommons.org/licenses/by/3.0)]. 
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Figure 7. San Antonio de los Cobres, the main village. Photographer: Florencia Harari. 
The main village San Antonio de los Cobres is located 160 km from the city of Salta, the 
capital of the province. The nine other villages are located at 40-216 km from the main 
village (Table 2). During the rain period (from January to March), the dirt roads are usually 
destroyed, limiting the accessibility from San Antonio de los Cobres to the surrounding 
villages, as well as to the city of Salta.  
In order to facilitate the organization of the health care services in the area, the Ministry of 
Health in Salta divided San Antonio de los Cobres geographically into 11 areas and grouped 
all the 20 “administrative areas” (11 in San Antonio de los Cobres and the nine surrounding 
villages) into a so-called “Operative Area XXIX”. The hospital Dr. Nicolás Cayetano Pagano 
is located in the main village and basic health service to the entire area is provided by three 
medical doctors, several nurses and nurse assistants. The Primary Health Care office is 
located next to the hospital and is integrated by 11 primary health care workers and 3 
supervisors. Each surrounding village has a primary health care clinic, where assistance is 
provided by a nurse and a primary health care worker, with the exception of Cobres and Tolar 
Grande where also a medical doctor is available. In total, there are 23 primary health care 
workers who visit the families in all villages on a regular basis, from 1 to 4 times every 3 
months (depending on the specific needs of the families) to update demographic information, 
including migration, health status and pregnancies. The annual birth rate is about 200 in the 
study area and the overall infant mortality rate is about 41 per 1000 born infants (Alduncin et 
al. 2005).  
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The Puna region is an arid mountain highland characterized by dry summers (December-
February) with daytime temperatures around 20° C and cold and windy winters (June-
August, -20° C and wind speed up to 80km/h). Inhabitants are mostly of indigenous origin, 
almost exclusively belonging to the Kolla community. Only a few inhabitants belong to the 
Atacama and Tastil communities. About 2/3 of the families own their houses, often built of 
adobe, with mud or cement floor and roofs made of tin/stones or straw/wood (Figure 8). The 
local economy is based on trading (e.g. handcrafts) and breeding of llamas, goats and sheep, 
as well as working in mines. The diet is largely of animal origin (meat and some dairy 
products but essentially no fish) with vegetables, potatoes and corn.  
 
Figure 8. House built of adobe with roof made of straw located in Casa Colorada (40 km from San Antonio de 
los Cobres). Tanks contain drinking water. Photographer: Florencia Harari. 
The source of drinking water in San Antonio de los Cobres is a natural spring (“Agua de 
Castilla”) located approximately 10 km away. From this spring, water is first pumped to a 
series of sand filters, and since a few years back, to an arsenic treatment plant. Thereafter, the 
water is transferred to a chlorination station before being distributed throughout the village. 
The presence of elevated arsenic concentrations in the drinking water in San Antonio de los 
Cobres is known since long (Vahter et al. 1995). More recently, the presence of elevated 
lithium, boron and cesium concentrations were discovered (Concha et al. 2010). The arsenic 
treatment plant was installed a few months before the start of the present study, decreasing 
the arsenic concentrations in the drinking water of San Antonio de los Cobres from ~200 
μg/L (Concha et al. 2010) down to about 30 μg/L during the study period (Figure 15).  
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4.2 STUDY DESIGN AND PARTICIPANTS 
The study in Paper I was designed to evaluate the kinetics of lithium and boron at delivery 
and in the post-partum period based on samples available from two studies performed 
previously. The studied women were from San Antonio de los Cobres (n=11), i.e. our main 
study site in northern Argentina (with elevated lithium and boron in the drinking water), and 
from two other study areas: one was Arica (n=24) in northern Chile with low lithium (60 
μg/L) but high boron (8,000 μg/L) concentrations in the drinking water, and the other was 
Santiago (n=11), the capital of Chile, with low concentrations of both lithium (~20 μg/L) and 
boron (~190 μg/L) in the drinking water (Figure 9). The women from San Antonio de los 
Cobres (included in Paper I) were recruited in 1996 as part of another study investigating the 
early-life exposure to arsenic (Concha et al. 1998a). The women from Arica and Santiago 
were recruited in 2010, as part of a study investigating early-life exposure to lead and arsenic 
through breast-feeding. 
For the purpose of the studies in Papers II-IV, we invited all pregnant women living in the 
Operative Area XXIX with estimated delivery date between October 2012 and December 
2013 to participate in a longitudinal mother-child cohort designed to evaluate potential health 
effects of early-life exposure to lithium and other water pollutants. Pregnant women were 
recruited with the assistance of the primary health care personnel, who knew the women and 
their addresses. The study was designed to see the pregnant women at least once during 
pregnancy; but preferably 2-3 times in order to obtain repeated measures of exposures and 
outcomes. The women were followed-up at delivery and 0-3 and 3-6 months later, when also 
the infants were included in the study. In Papers II-IV, only data during pregnancy and 
infant size measures at birth were included.  
Prior to each visit, a formal invitation was sent out to the pregnant women in each village 
with a suggested date and time. In case a woman was not able to attend at the scheduled date, 
she was offered to come any day before or after in order to achieve the highest possible rate 
of participation in the study. Since some women could not be located, we announced and 
welcomed all women to get involved in the study, using the local radio. Altogether, we 
visited the study area on seven occasions for collection of data and samples (October 2012, 
January, April, June-July, September-October and December 2013, and March 2014). In 
between on-site visits, close contact with the hospital and the primary health care workers 
was maintained regularly via e-mail and telephone. 
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In total, 221 women were pregnant during the study period out of whom 194 became enrolled 
(participation rate: 88%). Reasons for not participating included delivery before the 
recruitment (n=11), twin pregnancy (n=1), fetal loss before the recruitment (n=5), refusal or 
not located (n=6), and migration (n=4) (Figure 10 and Table 2). 
 
4.3 SAMPLING AND DATA COLLECTION 
For the study in Paper I (Figure 9), data regarding maternal age, parity, years of residency, 
gestational age at birth, birth weight and length were available. In San Antonio de los Cobres, 
samples of cord blood, maternal blood and urine, and infant urine had been collected at 
delivery as well as maternal blood, urine and breast milk, and infant urine at 2-4 weeks, 2-4 
months and 4-6 months after delivery (Concha et al. 1998a). All samples were kept frozen 
since collection. In Arica and Santiago, samples of maternal blood (RBC and plasma), urine 
and breast milk, and infant urine had been collected 2-4 months after delivery in 2010. Water 
samples had also been collected from each area. 
 
 
 
 
 
 
 
 
 
 
 
 
Paper I: 
Pilot study: 
Maternal and early-life 
exposure to lithium 
Delivery (n=11) 
2-4 weeks (n=10) 
Figure 9. Overview of study in Paper I.  
Mother-child pairs 
2-4 months (n=10) 
4-6 months (n=10) 
San Antonio de los 
Cobres, Argentina 
Arica, 
Chile 
Santiago, 
Chile 
2-4 months (n=24) 2-4 months (n=11) 
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221 became pregnant 
(from October 2012 until December 2013) 
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interviewed women 
(88% participation rate) 
Reasons for not recruiting: 
5 abortions before recruitment 
11 delivered before recruitment 
4 migration 
6 not located 
1 twin pregnancy 
2 abortions 
12 lacked exposure data 
Paper II: 
Fetal size 
Cross-sectional 
analyses: 
n=171 
Mother-child cohort  
Overview of the study population 
Papers II-IV 
180 
Paper III: 
Maternal thyroid 
function 
Paper IV: 
Maternal calcium 
homeostasis 
6 lacked birth 
measurements 
Analyses on birth size: 
n=174 
Analyses on fetal size: 
n=136 (179 observations) 
2
nd
 trimester: 81 
3
rd
 trimester:  98 
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 and 3
rd
 trimesters: 43  
44 lacked ultrasound 
measurements 
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5 positive for anti-TPO 
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(255 observations) 
1
st
 trimester: 27 
2
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 trimester: 82 
3
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 trimester:  146 
1
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 and 2
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1
st
 and 3
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 and 3
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2 lacked calcium markers 
Cross-sectional 
analyses: 
n=178 (latest pregnancy) 
n=144 (3
rd
 trimester) 
Longitudinal 
analyses: 
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(269 observations) 
1
st
 trimester: 27 
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 trimester: 98 
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1
st
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1
st
 and 3
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2
nd
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rd
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st
, 2
nd
 and 3
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: 16  Figure 10. Study design of Papers II-IV.  
4 lacked thyroid markers 
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For the studies in Papers II-IV, we interviewed the women during the first visit about age, 
place of birth, time and place of residency, ancestry, education years, occupation, family 
income, living conditions, personal and familial history of diseases, parity and other gyneco-
obstetrical history, dietary habits, tap water sources and type of water consumed (tap/bottled 
water), smoking habits, passive smoking, alcohol consumption, coca chewing, last menstrual 
period (LMP) and pre-pregnancy body weight, and we measured participant’s height. 
Gestational age was calculated based on the reported date of LMP (counting from the first 
day of the LMP), which was compared with fetal ultrasound-based estimation (see below). 
Height and pre-pregnancy body weight were used to calculated the pre-pregnancy body mass 
index (BMI; calculated as the pre-pregnancy body weight in kilograms divided by height in 
meters squared) and lean body mass (LBM) using the equation proposed by Watson and 
collaborators [LBM=(-2.097 + (0.1069*Height) + (0.2466*weight))/0.73; (Watson et al. 
1980)]. At each visit during pregnancy, we asked the women about potentially encountered 
health problems, collected blood and urine samples and measured body weight (HCG-
210QM, GA.MA ® professional, Italy; accurate to 100 g), LBM (Body Fat Monitor, HBF-
302, OMRON®, Tokyo, Japan) and blood pressure (aneroid sphygmomanometer, AB Henry 
Eriksson, Stockholm, Sweden).  
All women were asked to donate blood and spot-urine samples at baseline and at each follow-
up visit. We also repeatedly collected water samples (20 mL polyethylene bottles) during the 
whole study period. All samples were collected at the hospital, at the local primary health 
care clinics or, in a few cases, at home. Whole blood samples were collected in Trace 
Elements Sodium Heparin tubes (Vacuette®; Greiner bio-one, Kremsmünster, Austria) and 
Table 2. Overview of the study sites and of the recruited pregnant women and collected samples in each 
village for Papers II-IV between October 2012 and December 2013. 
Village 
Distance from 
San Antonio 
de los Cobres 
Inhabitants 
by Dec. 31st, 
2013 
N Pregnant 
women from 
Oct. 2012 to 
Dec. 2013 
Total recruited 
and sampled 
Trimesters 
1st 2nd 3rd 
N  
women 
N 
samples 
N  
women 
N  
women 
N  
women 
San Antonio de los Cobres  -- 5,893 165 138 220 26 77 117 
Cobres 60km 350 12 11 18 3 5 10 
El Palomar 78km 198 4 4 5 0 2 3 
El Toro 80km 198 1 1 1 0 0 1 
Esquina de Guardia >45km 182 6 2 3 1 2 0 
Las Cuevas 40km 183 7 4 5 0 1 4 
Olacapato 60km 462 10 9 17 2 6 9 
Pocitos 110km 165 2 1 1 0 1 0 
Santa Rosa de los P. G. 60km 307 8 7 9 0 4 5 
Tolar Grande 216km 197 6 3 3 0 1 2 
Total 8,135 221 180 282 32 99 151 
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Trace Elements Serum Clot Activator tubes (Vacuette ®; Greiner bio-one, Kremsmünster, 
Austria) using butterfly needles (BD Safety-Lok™, Vacutainer®, Bencton, Dickinson and 
Company, Franklin Lakes, USA). We extracted plasma and serum by centrifugation for 10 
minutes at 3000 rpm, 15 minutes after blood withdrawal. Hemoglobin levels were measured 
in whole blood using HemoCue® 201+ (HemoCue AB, Ängelholm, Sweden).  
Spot-urine samples were collected using disposable plastic cups and transferred to 24 mL 
trace-element free polyethylene bottles. All participating women received instructions on wet 
wipe cleaning and appropriate mid-stream urine sample collection in order to avoid 
contamination. During the fieldwork, we measured the urinary specific gravity using a hand 
refractometer (Atago, Japan) and we checked the content of glucose, proteins, blood, pH, 
ketones and nitrites using Combur®-7 test stripes (Roche Diagnostics, Mannheim, Germany). 
We also measured urinary albumin in all samples using HemoCue® Albumin 201 System 
(HemoCue AB, Ängelholm, Sweden).  
All samples were kept frozen at -20°C until transported to Karolinska Institutet, Sweden, 
where they were stored at -80°C until analysis. Samples were analyzed within 2 months after 
collection. 
 
4.4 EXPOSURE ASSESSMENT 
To assess the exposure to lithium in Paper I we measured the lithium concentrations in 
maternal whole blood and urine samples collected after delivery, as well as in cord blood, 
breast milk, infant urine and water. For Papers II-IV, the concentrations of lithium were 
measured in maternal whole blood and urine during pregnancy and in drinking water. Other 
elements found at elevated concentrations in the drinking water, such as boron, arsenic and 
cesium, were also analyzed in the different media. 
Lithium and all other trace elements were analyzed using inductively coupled plasma mass 
spectrometry (ICP-MS). All sample preparation and trace element analyses were performed 
at the Unit of Metals and Health, Institute of Environmental Medicine, Karolinska Institutet 
in Stockholm, Sweden.  
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4.4.1 Water lithium 
Water samples were collected at each visit during the whole study period. Each village has its 
own water supply, used for drinking water purposes by most pregnant women. In a very few 
cases, when women lived outside the villages and obtained water from different 
sources/springs, water samples were taken from those sources as well.  
Because of the occurrence of highly varying concentrations of lithium but also of arsenic, 
boron and cesium in the drinking water in the study area, all these elements were measured 
by ICP-MS [Agilent 7500ce (for Paper I) and Agilent 7700x (for Papers II-IV), Agilent 
Technologies, Tokyo, Japan], with the collision/reaction cell in no gas mode (lithium, boron 
and cesium) or helium mode (arsenic). Before analysis, water samples were diluted 1:10 with 
1% nitric acid (65% w/w, ppb-trace analysis grade, Scharlau, Scharlab S.L., Sentmenat, 
Spain). 
 
4.4.2 Biomarkers 
4.4.2.1 Blood lithium 
In order to test for potential trace element contamination of the sampling equipment used in 
the studies in Papers II-IV, that would invalidate the measured specimen concentrations, we 
performed trace element tests for each type of blood sampling tube using overnight extraction 
by weak nitric acid (0,03 M HNO3, ppb-trace analysis grade, Scharlau, Scharlab S.L., 
Sentmenat, Spain) at room temperature. The obtained concentrations of the trace elements of 
interest are presented in Table 3. The Trace Elements Serum Clot Activator tubes showed a 
severe contamination of lithium (37 µg/L extracted from the tubes, as compared to an overall 
median lithium concentration of 24 µg/L in blood collected in non-contaminated tubes in 
Papers II-IV), invalidating the use of lithium serum measurements in samples collected in 
such tubes.  
 Table 3. Trace elements concentrations (µg/L) from leaking tests for blood sampling tubes used for 
extraction of serum and plasma. 
 
Element LOD* 
Trace Elements Serum 
Clot Activator tubes 
Trace Elements Sodium 
Heparin tubes 
Trace Elements Sodium Heparin 
tubes + Butterfly needle 
Arsenic 0.0021 <LOD 0.0036 0.0035 
Boron 0.00047 0.26 0.73 0.41 
Calcium 0.29 20  12 11 
Cesium   0.00042 0.007 0.003 0.0038 
Lithium 0.0046 37 <LOD 0.068 
Magnesium   0.033 226 153 158 
Phosphorus   5.4 <LOD <LOD <LOD 
Selenium 0.0077 <LOD <LOD <LOD 
 *Limit of detection (µg/L).   
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The therapeutic window of lithium in patients undergoing lithium therapy is commonly 
assessed by the lithium concentrations in the patients’ plasma or serum (Grandjean and 
Aubry 2009a). Due to the severe lithium contamination in the blood sampling tubes (Trace 
Elements Serum Clot Activator tubes, Vacuette ®; Greiner bio-one, Kremsmünster, Austria), 
we could not make use of serum lithium concentrations as exposure marker in Papers II-IV. 
To evaluate the validity of the lithium concentrations in whole blood as a biomarker of 
exposure, we compared the concentrations with those measured in a subgroup of plasma 
samples (n=20) collected in non-contaminated tubes. We found an excellent correlation 
between lithium concentrations in whole blood and in plasma (Figure 11), indicating that the 
lithium concentration in whole blood is indeed a reliable marker of internal dose. Also, for 
the purpose of the present study, blood lithium is a more relevant measure as it has the 
possibility to cross the placenta and reach the fetus and thus, it better reflects the fetal 
exposure than does the lithium concentration in water or urine.  
 
Figure 11. Scatter plot of lithium concentrations in plasma and blood (n=20). 
 
For the study in Paper I, prior to the analyses of the available whole blood samples by ICP-
MS, approximately 0.5 g of each blood sample was first mixed with 3 mL of deionized water 
and 2 mL of nitric acid (65% suprapur, Merck, Darmstadt, Germany) and digested at 250° C 
for 30 minutes using a Milestone ultraCLAVE II microwave digestion system (EMLS, 
Leutkirch, Germany). This method has been used for other elements as described previously 
(Kippler et al. 2009). After digestion, samples were diluted to a final nitric acid concentration 
of 20%.  
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For the studies in Papers II-IV, an alkali dilution method for lithium and multiple other trace 
elements in blood was developed (Lu et al. 2015). We used aliquots of only 0.2 g of blood 
samples and diluted them 1:25 with an alkali solution and internal standards, as described in 
Papers II-IV and elsewhere (Lu et al. 2015). The mixture was sonicated for 5 minutes and 
centrifuged at 2000 rpm for 5 minutes before analyzing the samples by ICP-MS. This method 
was found to provide a better limit of detection (LOD) and analytical stability for blood 
lithium measurements compared with the conventional acid digestion (Lu et al. 2015).  
 
4.4.2.2 Urinary lithium 
Urine samples were analyzed to compare the trace element concentrations with those in blood 
and water. In Papers I-IV, urine samples were analyzed for lithium, boron and cesium, using 
the same method as for the water samples. Assessment of arsenic exposure was based on the 
sum concentrations of inorganic arsenic and its methylated metabolites [methylarsonic acid 
(MMA) and dimethylarsinic acid] in urine, determined using high-performance liquid 
chromatography coupled with hydride generation and ICP-MS (Fangstrom et al. 2008; Harari 
et al. 2013). The correlation between concentrations of sum of arsenic metabolites and total 
arsenic (measured using direct ICP-MS with the method described for water arsenic) was 
0.97 (p<0.001), supporting reliable analytical data. 
For comparison and quality control of the lithium measurements, all the urine samples from 
Papers II-IV were also analyzed using an alkali method in which the samples were diluted 
1:10 using 0.1% ammonium hydroxide (NH4OH 25% w/w, Suprapur®, Merck, Darmstadt, 
Germany). The acid and alkali methods gave essentially the same results (rs=0.98; n=288; 
Figure 12). Thus, the lithium measurements, analyzed using the acid method, were used for 
exposure assessment.  
 
Figure 12. Scatter plot of lithium urinary concentrations analyzed with the acid vs. alkali method (n=288). 
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In order to investigate the inter-day and intra-day variations in the lithium concentrations in 
urine, we measured lithium in urine samples from a previous study on arsenic in the same 
study area (Concha et al. 2002). Inter-day variation was assessed by collection of daily spot 
urine samples (at the same time of the day) from 15 women during 5 consecutive days. The 
intra-day variation was assessed by collection of all urine (each void in a separate container) 
produced during 72 hours in 7 women.  
The mean intra-day variation in the specific gravity-adjusted lithium concentrations in urine 
was +/-17% (Figure 13A), while the mean inter-day variation was +/-9% (Figure 13B).  The 
average lithium concentrations in urine of day 1, 2 and 3 (from the intra-day samples) were 
highly correlated [rs=0.50 (day 1 vs. 2), rs=0.71 (day 1 vs. 3) and rs=0.86 (day 2 vs. 3)] and 
similar correlations were found in samples from the inter-day comparison (rs ranging from 
0.43 to 0.74). A diurnal variation in the lithium concentrations in urine might be due to 
reported circadian variations in the renal excretion of lithium (Kyroudis et al. 1987; Shetty et 
al. 2012). In our study, the lithium concentrations in urine collected during morning/day time 
(average of day 1, 2 and 3: 1,845 μg/L, range 1,204-2,486) did not differ statistically from 
that in urine collected during evening/night time (1,997 μg/L, range 1452-2,543). Thus, 
lithium measurements in spot-urine samples seem to estimate the actual exposure to lithium. 
Although 24-hour urine samples (or first morning urine) would definitely provide a better 
exposure estimate than spot-urine samples, the collection of 24-hour urine samples has a high 
probability of incomplete sampling (Johansson et al. 1999) and was not feasible in the present 
study. Similarly, first morning urine sampling was not feasible. 
 
  
Figure 13. Individual intra-days (n=7; A) and inter-days (n=15; B) variation of the lithium concentrations in 
urine (adjusted for specific gravity). 
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To compensate for variations in the dilution of urine, we adjusted the measured element 
concentrations to the mean specific gravity (1.019 g/mL), measured by a hand refractometer 
(Atago, Japan) during the fieldwork, as well as to the mean urinary osmolality (694 
mOsm/kg; range 141–1174), measured later at Karolinska Institutet by a digital cryoscopic 
osmometer (OSMOMAT® 030, Gonotec Gesellschaft für Meß- und Regeltechnik mbH, 
Berlin, Germany). The lithium concentrations in urine adjusted for specific gravity were 
highly correlated with those adjusted for osmolality (rs=0.98, p<0.001, n=288, Figure 14). 
Urinary lithium concentrations adjusted for osmolality were chosen as an exposure biomarker 
in urine in Papers II-IV since the specific gravity is influenced by urinary protein and 
glucose (Parikh et al. 2002). Creatinine adjustment, other commonly-used alternative, was not 
chosen as it is known to be markedly affected by muscle mass, age and meat intake (Nermell 
et al. 2008; Suwazono et al. 2005). 
 
 
Figure 14. Scatter plot of the lithium concentrations in urine adjusted for osmolality and specific gravity 
(n=288). 
 
4.4.2.3 Breast milk 
In Paper I, breast milk samples were analyzed for lithium using the same method as for the 
blood samples in the same study, i.e. acid digestion of samples prior the ICP-MS analysis. 
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4.4.3 Reference materials and limits of detection 
In order to secure the analytical accuracy, we analyzed all the samples together with reference 
materials. To the best of our knowledge, there are no certified reference materials for lithium 
in blood, serum, RBC, urine or breast milk. Instead, we used commercially available 
reference materials with recommended values. For lithium in drinking water, we used the 
certified reference material SRM 1643e Trace Elements in Water [National Institute of 
Standards and Technology (NIST), Gaithersburg, USA].  
In general, the values that we obtained were in satisfactory agreement with the 
reference/recommended values. Results of reference materials used for other elements are 
summarized in each individual paper. 
Limits of detection were calculated as 3 times the standard deviation of the blanks. Results 
for the used reference materials and LOD for lithium are presented in Table 4.  
 
Table 4. Limits of detection and obtained and reference values of the reference materials used for analytical 
quality control for lithium measurements. 
 
Paper Quality control for Method LOD (µg/L) n Reference  material Reference value Obtained value 
I Blood and RBC Acid 0.18 and 0.028 6 SeronormTM 0503109 L-2a 1.9 (1.8-2.0)a 1.5 (1.2-2.0)a 
 Breast milk and plasma Acid 0.028 and 0.14 10 SeronormTM NO0371y L-2b  10.6 (9.8-11)b 9.1 (7.1-13)b 
 Urine Acid 0.032 10 SeronormTM NO2525a  7.9 (7.4-8.5)a 9.0 (4.9-14)a 
    9 SeronormTM OK4636a  15.8 (15-17)a 13 (7.7-19)a 
  Water Acid 0.032 11 NIST 1643ea  17.4 (16-19)a 16 (12-18)a 
II-IV Whole blood Alkali 0.0073 21 SeronormTM 1103128a  0.46  0.63 (0.48-0.89) 
    21 SeronormTM 1103129a 0.44 (0.41-0.47) 0.67 (0.21-0.96) 
 Urine Acid 0.20 36 SeronormTM 1011644 L-1a 7.0 7.9 (6.3-11) 
    37 SeronormTM 1011645 L-2a  7.0 7.6 (5.8-11) 
    14 NIST2670a High levela N/A 14 (12-16) 
  Water Acid 0.008 14 NIST1643ea 17.4 (16-19) 16 (15-18) 
a µg/L; b mg/L; N/A: not available; RBC: red blood cells; LOD: limit of detection; NIST: National Institute of Standards and Technology. 
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4.5 OUTCOMES 
4.5.1 Fetal and birth size measurements 
At 1-3 time-points during pregnancy, fetal growth was assessed by ultrasound measurement 
of the biparietal diameter (BPD), occipitofrontal diameter (OFD), head circumference 
(HC), abdominal circumference (AC), femur length (FL) and estimation of fetal weight 
(FW). The detailed description of the performance of the fetal measurements can be found 
in Paper II. Out of the 180 women included in the study, ultrasound measurements were 
obtained in 136, measured in October 2012, January 2013 and April 2013. The 
examinations were performed by an experienced senior obstetrician, using a portable 
ultrasound machine FFSonic, UF-4100, (Fukuda Denshi, Tokyo, Japan) available at the 
hospital in San Antonio de los Cobres. Each measurement was performed three times, each 
time using a new picture, after which the average was computed.  
 
In addition, weight, length and head circumference were measured at birth by the nurses at 
the hospital in San Antonio de los Cobres in most of the cases. Prior to the study start, we 
informed all health care personnel about the project and trained the medical personnel to 
perform the anthropometric measurements of the newborns at birth and to collect the samples 
of cord blood and placenta. Also, we established collaboration with the main gyneco-obstetric 
hospital in Salta and provided instructions for data and sample collection as well as sample 
collection kits. In this way, independently if women delivered in San Antonio de los Cobres 
or Salta, all data and sample collection at birth was performed in a standardized way. 
Thirty seven percent of the women delivered at the main hospital of the city of Salta, 3.5% 
in the ambulance on the way to Salta, 3.5% in the surrounding villages, 4% at home and the 
rest (52%) at the hospital in San Antonio de los Cobres.  
 
4.5.2 Markers of thyroid function 
To assess the maternal thyroid function, we selected the following markers in serum: TSH, 
T4, fT4, T3, fT3, Tg and TTR. All analyses were performed at the Department of Clinical 
Chemistry at the University Hospitals in Lund and Malmö, Sweden. The detailed description 
of each particular method can be found in Paper III. 
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4.5.3 Markers of calcium homeostasis 
We assessed the calcium homeostasis by the concentrations of intact parathyroid hormone 
(iPTH) in serum, 25-hydroxyvitamin D3 in plasma, and the serum and urinary concentrations 
of total calcium, phosphorus and magnesium. We also analyzed serum albumin to adjust the 
serum calcium concentrations. Analysis of iPTH, 25-hydroxyvitamin D3 and albumin were 
performed at the Department of Clinical Chemistry at the University Hospitals in Lund and 
Malmö, Sweden. Calcium, phosphorus and magnesium were analyzed by ICP-MS using the 
method described above for lithium measurements in blood and urine. The detailed 
description of each particular method can be found in Paper IV. 
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4.6 ETHICAL CONSIDERATIONS 
Studies in Papers I-IV were approved by the regional ethical committee at Karolinska 
Institutet, Stockholm, Sweden, and by the Ministry of Health, Salta, Argentina. The study in 
Paper I was also approved by the Ethical Committee of the Institute of Nutrition and Food 
Technology (INTA), University of Chile.  
Prior to recruitment of the pregnant women, we obtained written informed consent from all 
women after oral and written explanation of study details. For women below 18 years of age, 
informed consent was also obtained from the closest care giver. At the end of every meeting 
with each woman and her baby, the woman received a report of the results of the 
measurements performed during the visit (i.e. blood pressure, urine tests, hemoglobin, body 
weight, BMI, blood glucose, as well as weight, length and head circumference of her baby). 
Without prior announcement, in the last follow-up visit, every woman received a baby 
garment and a tissue bag as acknowledgement for their participation.  
In case any of the measurements showed abnormal results, these were communicated to the 
local medical doctors. Abnormalities found during the ultrasound examinations [i.e. heart 
malformation (n=1), renal cysts (n=1), polyhydramnios (n=1) oligoamnios (n=1)] were 
immediately reported to the local medical doctors who referred the patients to the main 
obstetric clinic in Salta. After completion of the analyses of thyroid function, abnormal values 
of TSH were reported to the hospital in San Antonio de los Cobres for additional follow-ups 
of the patients at the thyroid hospital “Dr. Arturo Oñativia” in Salta.  
On regular basis, we reported to and discussed the measured concentrations of the different 
trace elements in drinking water with the hospital in San Antonio de los Cobres, the primary 
health care clinics in the surrounding villages and the Ministry of Health in Salta. Also, 
results of the published articles have been reported to the Ministry of Health in Spanish. 
During the last visit to San Antonio de los Cobres, we prepared a meeting with the medical 
and health care personnel from all the villages to present preliminary results of the study on 
lithium and other elements during pregnancy. 
We also participated in meetings with the “Arsenic Group” in the city of Salta. This consists 
of representatives of different local governmental agencies and universities aiming at 
discussing and following up results concerning arsenic in drinking water in the province of 
Salta. We have assisted in the search of an alternative water source for San Antonio de los 
Cobres by collecting water samples and measuring the concentrations of multiple elements.  
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4.7 STATISTICAL ANALYSES 
For a detailed description of the different statistical methods used in this thesis, the reader is 
referred to the individual papers (Papers I-IV).  
Depending on the nature of the data, different statistical approaches were applied. All 
statistical analyses were performed using either IBM ® SPSS ® Statistics 18.0 (SPSS, 
Chicago, IL, USA), Stata (StataCorp LP. 2012. Stata Statistical Software: Release 12.1. 
College Station, TX, USA) or R [version 3.2.1, (R Core Team 2015)]. 
Relationships between exposure measures, outcome variables and covariates were assessed 
using Spearman’s rank correlation coefficients or linear mixed-effects regression for 
longitudinal data. We used scatter plots to visually evaluate the different relationships. We 
tested differences between groups (e.g. tertiles of blood lithium) using Kruskal-Wallis H rank 
test or chi square test.  
Associations between lithium exposure and the different outcomes were assessed using linear 
regression (cross-sectional data) or linear mixed-effects regression models (longitudinal data). 
For dichotomous outcome variables (e.g. vitamin D3 concentrations < and >50 nmol/L), we 
used mixed-effects logistic regression with random intercept (longitudinal data) and binomial 
logistic regression (cross-sectional data).  
We also performed quantile regression analyses (for both cross-sectional and longitudinal 
data) to assess the association of blood lithium on the whole distribution of the outcomes. In 
all cases, we based the estimates, confidence intervals (CI), and p-values on 500 bootstrap 
samples and used Wald test to evaluate differences between the estimated regression 
coefficients across the quantiles.  
The regression models were adjusted for covariates known to affect the outcome measures or 
that influenced the estimates more than 10% (Sullivan 2008). Whenever necessary, i.e. to get 
the best fit of the data with normally distributed residuals, the exposure variables were log2-
transformed. 
Different sensitivity analyses were performed to test e.g. the influence of extreme values as 
well as the impact of diseases (infections and preeclampsia) in the different associations. 
 
 
 
  33 
5 RESULTS AND DISCUSSION 
In this section, the main findings of the thesis are presented and discussed, with reference to 
the actual paper. Some unpublished data are also presented. For further details, the reader is 
referred to the individual papers (Papers I-IV).   
 
5.1 MATERNAL AND EARLY-LIFE EXPOSURE TO LITHIUM  
5.1.1 Lithium and other elements in drinking water 
Elevated concentrations of lithium, boron and cesium in drinking water in our study area 
were discovered about five years ago (Concha et al. 2010), while elevated arsenic 
concentrations have been known for several decades (Vahter et al. 1995). The highest lithium 
concentrations in the drinking water were found in San Antonio de los Cobres (mean 718 
μg/L, range 528-837, n=58; Table 5) and in a small natural spring 20 km east of Cobres 
providing water for just one family (range 958-1,660 μg/L, n=3). The concentrations of 
lithium, arsenic and cesium in the other villages were at least 1/5 of those in San Antonio de 
los Cobres, with the lowest found in Tolar Grande. The highest boron concentrations were 
found in San Antonio de los Cobres, Esquina de Guardia and Cobres and the lowest in Tolar 
Grande and Palomar (Table 5). 
Table 5. Average concentrations (range) of lithium, boron, arsenic and cesium (all expressed in μg/L) in the 
drinking water in the 10 study villages from October 2012 until April 2014. 
 
Village n Lithium Boron Arsenic Cesium 
San Antonio de los Cobres 58 718  (528-837) 5,610  (3,421-6,925) 114  (41-244) 323  (101-410) 
Cobres 13 77  (29-162) 3,433  (1,356-6,655) 14  (1.7-89) 0.25  (0.01-1.7) 
El Palomar 9 13  (5.0-71) 541  (314-1,866) 4.0  (1.0-17) 0.047  (0.01-0.22) 
El Toro 17 66  (7.6-203) 1,806  (449-5,995) 13  (2.3-71) 0.084  (0.02-0.20) 
Esquina de Guardia 8 117  (52-123) 5,781  (3,311-6,239) 13  (6.2-13) 4.4  (3.0-6.2) 
Las Cuevas 15 98  (17-159) 1,521  (388-2,256) 27  (0.83-48) 0.37  (0.02-2.6) 
Olacapato 8 23  (17-29) 668  (448-919) 9.3  (4.1-13) 5.5  (3.2-7.0) 
Pocitos 6 99  (22-132) 869  (438-1,081) 44  (17-58) 14  (5.0-22) 
Santa Rosa de los Pastos Grandes 6 112  (18-242) 2,403  (426-4,620) 46  (12-141) 34  (10-65) 
Tolar Grande 1 8.2 377 3.2 0.060 
 
Water samples have been repeatedly collected in San Antonio de los Cobres since 1994, 
when the first studies on arsenic in this area were performed (Vahter et al. 1995). We 
analyzed all the samples available since then (n=104), for arsenic, lithium, boron and cesium 
and investigated changes in the concentrations over time (Figure 15). The lithium and boron 
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concentrations had similar patterns of variation, with the highest concentrations found in 
December 2008 (summer) and the lowest in November 2012 and September 2013 (spring), 
but there were no clear seasonal variations or influence of the rain period (January-March). 
Lithium and boron concentrations in the drinking water were highly correlated (rs=0.91). 
Lithium was also highly correlated with water arsenic (rs=0.88) and cesium (rs=0.79). 
The cesium concentrations in drinking water appeared to be more stable over time than the 
other elements and slightly lower concentrations were found in July, September and 
December 2013. The arsenic concentrations were quite stable until November 2011, as 
previously reported (Concha et al. 2006). However, following the installation of the arsenic 
filter close to the main water source, the arsenic concentrations dropped to about 30 μg/L. 
Conversely, arsenic concentrations seemed to increase again after the completion of this 
study, in April 2014, suggesting that the filter might not be working or in use. 
 
 
Figure 15. Average lithium, boron, cesium and arsenic concentrations in drinking water in San Antonio de los 
Cobres from November 1994 till April 2015 (n=104). Lithium, arsenic and cesium concentrations are expressed 
in μg/L, and, to fit the scale, boron concentrations are expressed in μg/dL. 
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5.1.2 Lithium in maternal blood and urine 
5.1.2.1 Lithium concentrations in blood and urine during pregnancy 
As mentioned above, the main biomarker selected to assess lithium exposure was blood 
lithium. The overall median lithium concentration in maternal blood and urine during 
pregnancy was 25 µg/L and 1,404 µg/L, respectively, both with wide ranges of distribution 
(1.9-145 and 105-5,185, respectively; Papers II-IV and Figure 16A and 16B). Thus, the 
concentrations in urine were 56 times higher, on average, than those in blood. 
 
 
Figure 16. Distribution of the lithium concentrations (average for women with 2-3 measurements) in maternal blood (A) and 
urine (B) during pregnancy (n=180) (Papers II-IV).  
 
The lithium concentrations in blood and urine (average for women with 2-3 measurements) 
were highly correlated (rs=0.84, Paper II, Figure 17B). To a lesser extent, lithium 
concentrations in blood were correlated with those in water (rs=0.40) (Figure 17A). Similar 
correlations were found between urinary lithium and drinking water (rs=0.44). These weaker 
correlations between blood/urinary lithium and water lithium are likely explained by 
differences in the intake of drinking water, potential variations in the lithium concentrations 
in the water, and the intake of lithium-free bottled water. Indeed, the correlation between 
blood and urinary lithium with that in drinking water was higher in women reporting 
exclusive intake of tap water (rs=0.48 for blood and rs=0.50 for urine), compared with those 
reporting additional intake of bottled water (rs=0.31 for blood and rs=0.40 for urine). In 
addition, exposure through other sources such as food might have contributed to the weaker 
correlation with lithium in the tap water. 
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Figure 17. Scatter plot showing the lithium concentrations in blood and drinking water (A), and those in blood 
and urine (B) (n=180) (Papers II-IV). 
 
A marked inter- and intra-individual variation in the lithium concentrations in urine of 
lithium-treated patients has been reported (Kyroudis et al. 1987) as well as a much weaker 
correlation between plasma and urinary lithium [rs=0.23, p=0.10; (Shetty et al. 2012)] 
compared with that in our study, suggesting that the correlation between plasma/blood and 
urinary lithium might be dependent on the dose, the dosage regimen or genetic differences in 
the excretion of lithium. In the case of continuous lithium exposure, such as from water and 
food, the concentration in blood is likely to reach a steady state and to estimate a more long-
term exposure. 
 Lithium concentrations in plasma or serum are commonly used for monitoring the 
therapeutic range in patients on lithium therapy (Grandjean and Aubry 2009a). In our study, 
the lithium concentrations in plasma appeared to be about 1.5 times that measured in whole 
blood in the same individuals (Figure 11), with very low inter-individual variation (95% CI 
1.4-1.6, n=20). Transforming our highest observed blood lithium concentration (i.e. 161 
µg/L) into corresponding plasma concentration (242 µg/L), it would still be only 7% of the 
lower range of serum lithium levels during lithium therapy (~5,500-8,300 µg/L, i.e. 0.8-1.2 
mmol/L) (Grandjean and Aubry 2009a; Malhi et al. 2011). However, it was at least 30 times 
higher than what was described in the Chilean study (range 4.1-8.0 µg/L; Paper I). In 
unexposed people, the lithium concentration in plasma is generally about 1 μg/L (Alimonti et 
al. 2005). 
 
5.1.2.2 Lithium concentrations in blood and urine during pregnancy and post-partum 
Based on linear-mixed effects models with random intercept (longitudinal analyses), the 
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pregnancy and to 3 months post-partum (0.83 µg/L per week, 95% CI 0.67-0.99; Figure 18), 
along with an increase in the urinary lithium concentrations (19 µg/L per week, 95% CI 6.9-
30). After this period, at 3-6 months after delivery, the lithium concentrations in urine seemed 
to decrease again (Figure 19). Please note that the results from samples collected during 
pregnancy are described in Papers II-IV, while those from the post-partum period are 
presented only in the Figures 18 and 19. 
Our findings are in disagreement with the reported decrease in the lithium concentrations in 
plasma in lithium-treated pregnant women during late pregnancy (Grandjean and Aubry 
2009a), which is suggested to happen due to the physiological increased glomerular filtration 
rate and plasma expansion occurring during gestation. This is the reason why lithium doses 
are recommended to be increased in late gestation (Grandjean and Aubry 2009a).  
 
Figure 18. Scatter plot of maternal blood lithium concentrations (µg/L) during pregnancy and post-partum 
(n=360 measurements, 1-4 measurements per woman, n=180 women). LMP: last menstrual period. Blood 
samples were collected only up to 3 months after delivery. Dashed line represents a lowess line between blood 
lithium concentrations and the number of days from the LMP. Dotted line represents the average gestational age 
at delivery. 
 
The increased glomerular filtration rate during pregnancy would only support the finding of 
increased lithium concentrations in urine and not in blood in the present study. It can be 
speculated that the increased lithium concentrations in blood during pregnancy and post-
partum might instead be due to an increased activity of the sodium-lithium counter 
transporter in the erythrocytes (Worley et al. 1982). Increased consumption of drinking water 
during pregnancy could be an alternative explanation. Moreover, because a large part of the 
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1972), it is likely that an increased bone resorption during late pregnancy and after delivery 
(Åkesson et al. 2004) releases the accumulated lithium from the bones, explaining the 
increase in both blood and urinary concentration of lithium observed up to 3 months after 
delivery. The decrease in urinary lithium concentrations at 3-6 months post-partum is in 
agreement with the resolution of the physiological kidney changes that occur during 
pregnancy (Cheung and Lafayette 2013).  
 
Figure 19. Scatter plot of maternal urinary lithium concentrations (µg/L) during pregnancy and puerperium 
(n=360 measurements, 1-4 measurements per woman, n=180 women). LMP: last menstrual period. Urine 
samples were collected up to 6 months after delivery. Dashed line represents a lowess line between urinary 
lithium concentrations and the number of days from the LMP. Dotted line represents the average gestational age 
at delivery. 
 
 
5.1.3 Lithium transfer through the placenta 
The geometric mean lithium concentration in the cord blood samples from 1996 collected in 
San Antonio de los Cobres (Paper I, n=10) was 70 μg/L (range 30-105), compared to 47 
µg/L (range 20-77) in the maternal blood at delivery, indicating passage of lithium through 
the placenta. Furthermore, the lithium concentrations in cord blood and maternal blood at 
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and maternal lithium was lower (rs=0.48, n=76), likely due to the marked variation in 
maternal blood lithium with increasing gestational week also within the third trimester. 
In support of a pronounced transfer of lithium to the fetus (Paper I), we found that the 
geometric mean lithium concentration in the first infant urine in life was 600 μg/L (range 
140-1,680, n=7), almost half of that in maternal urine at delivery (geometric mean 1,400 
μg/L, range 810-2,300, n=11). 
 
Figure 20. Scatter plot of lithium concentrations in maternal and cord blood (Paper I).  
 
A case-study of a patient on lithium therapy showed similar lithium concentrations (about 
2,000 μg/L) in maternal and newborn serum at birth (Sykes et al. 1976), supporting our 
findings of a marked transfer of lithium through the placenta at both low and high exposure 
levels. Indeed, a more recent clinical study showed good agreement between concentrations 
in cord and maternal blood within a range of lithium doses of 300-1800 mg/day (Newport et 
al. 2005). 
The transfer of lithium through the placenta occurs most probably during the whole gestation, 
including the sensitive embryonic period when the organogenesis takes place. This is 
supported by the fact that lithium therapy has been associated with the occurrence of a series 
of developmental abnormalities, particularly in experimental studies [Table 1 and (Morgan et 
al. 2003)] and therefore, lithium is classified as teratogenic (category D) by the U.S. Food and 
Drug Administration. Suggested mechanisms of lithium transfer through the placenta are: 
bidirectional passive diffusion, as well as fetal-maternal unidirectional active transfer 
involving sodium/potassium ATPase (Palavinskas et al. 1982). 
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5.1.4 Lithium transfer through the mammary gland 
The lithium concentrations in the infant urine decreased from 600 μg/L in the very first urine 
produced, to 120 μg/L (84-600) already at 2-4 weeks after birth (Paper I). Thereafter, the 
lithium concentrations in infant urine increased again to 380 μg/L at 4-6 months of age. The 
lithium concentrations in breast milk were on average 23 μg/L (range 8.8-53) at 2-4 weeks 
after delivery, 31 μg/L (17-53) at 2-4 months and 36 μg/L (24-54) at 4-6 months.   
The observed rapid decreased in the newborns’ urinary lithium concentrations, to 120 µg/L 2-
4 weeks after birth, reflects a fast neonatal renal excretion of lithium and a much lower 
exposure through breast-milk than prenatally. Thus, breast-feeding appeared to provide 
certain protection against infant lithium exposure. Previous studies indicated a similar 
protection level against arsenic in the drinking water (Concha et al. 1998b). Evidently, 
formula prepared from the drinking water containing elevated lithium concentrations had 
provided much higher exposure levels.   
The lithium concentrations in breast milk in our study were about half of that in maternal 
blood and both increased slightly but constantly after delivery (Paper I) and were highly 
correlated (rs=0.80, Figure 21). In line with the high maternal blood lithium concentrations in 
women on lithium therapy, also the concentrations in breast milk are much higher in treated 
mothers [700-3,500 μg/L; (Viguera et al. 2007)]. 
 
Figure 21. Scatter plot of lithium concentrations in maternal blood and breast milk (Paper I).  
 
5.2 LITHIUM EXPOSURE AND FETAL SIZE 
The study in Paper II is the first ever to investigate the potential impact of maternal exposure 
to lithium from drinking water on human fetal development. The study was based on fetal 
ultrasound measurements performed during pregnancy as well as measurements at birth.  
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5.2.1 Lithium exposure and fetal measurements  
Out of the 180 women with available exposure data, 134 had at least one ultrasound 
measurement of the fetal size [head (BPD, OFD, HC), abdomen (AC), length (FL) and 
estimated weight (FW)] in the 2nd and/or 3rd trimester. Measurements in the 1st trimester were 
not included, as mainly crown-rump length was measured in the first weeks of pregnancy. 
Blood lithium was used as exposure biomarker, supported by the lithium concentrations in 
urine. 
 The correlation between the different fetal measurements was strong within the 2nd (rs>0.98) 
and the 3rd (rs>0.83) trimesters, but those were not correlated with blood or urinary lithium, 
urinary arsenic, serum boron, blood cesium, maternal age, parity, educational level, height, 
residence time or parental monthly income. In individuals with two fetal measurements 
(n=43), the different measurements were also strongly correlated between the 2nd and the 3rd 
trimesters (rs=0.72-0.83). 
In the multivariable-adjusted linear regression models (n=136 women, n=179 measurements), 
both blood and urinary lithium were inversely associated with all measures of fetal size in the 
2nd trimester, although these associations did not generally reach significance (Figure 22). 
The effect sizes were in the order of 1/8 SD for all fetal measures. In the 3rd trimester, there 
was no association between blood lithium and fetal size measurements, although the 
associations with urinary lithium were generally inverse but not statistically significant. 
Neither urinary arsenic, nor serum boron or blood cesium were significant in the statistical 
models.   
 
 
Figure 22. Multivariable-adjusted estimates (Beta coefficients and 95% CI) for the associations between blood 
lithium and fetal measurements. BPD: biparietal diameter (cm), OFD: occipitofrontal diameter (cm), HC: head 
circumference (cm), AC: abdominal circumference (cm), FL: femur length (cm), FW: fetal weight (in grams 
divided by 100 to fit the scale). Estimates expressed as changes per every 25 μg/L increment in blood lithium. 
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Because early embryonic and fetal stages are the most sensitive periods in life (Figure 3), 
one could speculate that, despite the fact that none of the associations were clearly 
statistically significant, lithium impairs the fetal development already in early gestation. This 
early embryonic and fetal stages are also the most sensitive periods for the exposure to other 
chemicals (Barouki et al. 2012). Maybe the lack of associations in the 3rd trimester could also 
be due to the known increased variation in the ultrasound measurements with increasing 
gestational age (Geirsson 1991), along with the above mentioned variation in the blood and 
urinary concentrations of lithium during pregnancy and the limited sample size for these 
analyses to overcome such variations. 
5.2.2 Lithium exposure and measurements at birth 
The average birth weight in the study population was similar in both boys and girls and was 
on average 3,022 g (range 1,250-4,500), which is lower than the average birth weight in 
European countries [~3,500 g, (Pedersen et al. 2013)] and that reported in Buenos Aires, the 
capital of Argentina [~3400 g, (Grandi 2003)]. Eight percent of the newborns had low birth 
weight (<2,500 g) and 18% were born preterm [average gestational age at birth 38.5 weeks 
(range 29-42)]. The average birth length and head circumference were 48 and 34 cm, 
respectively. 
After adjusting for gestational age at birth, parity, parental monthly income, maternal height, 
infant sex, arsenic in urine, boron in serum and cesium in whole blood, the linear regression 
models showed an inverse association between maternal blood lithium and birth length (about 
0.5 cm per every 25 μg/L increment in the average blood lithium concentrations across 
pregnancy) (Figure 23). Similarly, newborns to mothers in the highest tertile of lithium 
exposure (median blood lithium 42 μg/L) were on average 0.8 cm shorter than those in the 
lowest tertile of exposure (median blood lithium 11 μg/L).  
Neither urinary arsenic, nor serum boron or blood cesium were statistically significantly 
associated with fetal size measurements in the multivariable-adjusted models. However, the 
estimates for the association between blood lithium and birth length were attenuated after 
adjusting the model for serum boron. Experimental studies have suggested that boron may 
impair the fetal size (WHO 2011). Thus, we cannot fully rule out that the associations 
observed in the present study are actually due to a combination of lithium and boron 
exposure. On the other hand, due to the high correlation between these two elements in 
drinking water (rs=0.91) and blood (blood lithium vs. serum boron, rs=0.77), the observed 
attenuation could be due to collinearity. In contrast, urinary arsenic and blood cesium did not 
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influence the estimates. The arsenic concentrations in the drinking water were lower during 
the study period due to the installation of an arsenic filter in the main study village, 
decreasing the exposure to arsenic. Also, women in the study area are known to metabolize 
arsenic more efficiently than other populations such as that in Bangladesh (Engstrom et al. 
2011). This, together with a lower arsenic exposure, might, at least partially, explain why 
arsenic was not statistically significant in the multivariable-adjusted models; i.e. women with 
a more efficient arsenic metabolism will excrete the most toxic arsenic metabolite (i.e. MMA) 
more rapidly, exposing the fetus to lower levels of such metabolite.  
The findings of associations between maternal lithium exposure and birth size are supported 
by those found with fetal measurements performed with ultrasound. That lithium may affect 
fetal growth has some support in the literature. Particularly, two studies in humans with 
lithium-treated patients reported lower birth weight in babies born to women undergoing the 
therapy, compared to controls (Table 1). Also, a series of experimental studies in mice, rats 
and monkeys, using doses from 7 to 400 mg/kg/day, as well as an in vitro study, have 
reported a decreased birth size in the exposed group (Table 1).  
 
 
Figure 23. Multivariable-adjusted estimates (Beta coefficients and 95% CI) for the associations between blood 
lithium and measurements at birth [weight (grams), length (cm) and head circumference (cm)]. Estimates for 
birth weight were divided by 100 to fit the scale. Estimates are expressed as changes per every 25 μg/L 
increment in blood lithium. 
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5.3 POTENTIAL MECHANISMS 
5.3.1 Disruption of the maternal thyroid function  
Impairment of the thyroid function is a common side effect of lithium medication (McKnight 
et al. 2012). Therefore, we wanted to elucidate whether lithium exposure through drinking 
water could influence the maternal thyroid function during pregnancy (Paper III). If so, this 
could be a potential underlying mechanism for the associations between maternal lithium 
exposure and fetal size. We measured a number of different thyroid markers in maternal 
serum and investigated their association with lithium exposure during pregnancy. The 
selected thyroid markers included: TSH, fT4, T4, fT3, T3, Tg and TTR. Nineteen, twelve and 
thirteen percent of the women showed TSH concentrations above the reference value in the 
1st (0.1-2.5 mIU/L), 2nd (0.2-3.0) and 3rd (0.3-3.5) trimesters, respectively. Eighty-three 
percent of those with abnormal values belonged to the highest tertiles of blood lithium 
(median blood lithium 42 μg/L, range 34-145). Also, 6% of the women had low fT3 values 
(reference value 3.7-7.7 pmol/L) in the 3rd trimester, and 78% of those belonged to the 
highest tertiles of lithium exposure. Only half of the women appeared to be iodine sufficient 
(i.e. urinary iodine >150 μg/L).  
The multivariable-adjusted quantile regression models showed that the blood lithium 
concentrations were positively associated with TSH, particularly in the lowest tail of TSH 
concentrations. Also, blood lithium was inversely associated with fT3, total T3 and TTR, 
particularly in the highest percentiles of the outcomes. No associations were found between 
blood lithium and fT4, T4 or Tg.  
Unexpectedly, blood cesium was also inversely associated with fT3 and T3 in the highest 
percentiles of the outcomes. Neither urinary arsenic, nor serum boron were significant in the 
models and they did not influence the associations with lithium and cesium. 
Impairment of the thyroid function during pregnancy might be detrimental for the fetal 
growth and development (Forhead and Fowden 2014). To the best of our knowledge, there is 
only one previous study investigating the thyroid function in relation to lithium exposure 
from drinking water (Broberg et al. 2011). This study was performed in the same study area, 
i.e. with the same level of exposure, in adult non-pregnant women (median age 34, range 12-
80), where urinary lithium was positively associated with TSH and negatively associated with 
fT4. No other thyroid markers were measured in that study. The lack of associations between 
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blood lithium and fT4 or T4 in this thesis might be explained by an elevated variation of the 
fT4 and T4 concentrations during pregnancy (Lockitch 1993). 
In medication and experimental studies, using much higher doses than those in the present 
thesis, lithium is suggested to impair the thyroid function in different ways. For example, by 
inhibiting the iodine uptake, the iodotyrosine coupling, the thyroxine secretion and the 
conversion of T4 to T3, or by altering the Tg structure (Berens et al. 1970; Burrow et al. 
1971; Terao et al. 1995). Lithium effects on the TSH levels could occur by inhibiting its 
stimulation by TRH, as lithium is known to cross the blood–brain barrier and accumulate in 
the hypothalamus (Mukherjee et al. 1976). This would in turn, inhibit TSH secretion and alter 
the whole chain of thyroid hormone production, which will conversely stimulate the TSH 
secretion (Figure 4) to abnormal levels.  
Another probable hypothesis is an inhibition of the production and release of thyroid 
hormones in the thyroid gland, as lithium is also known to accumulate there (Berens et al. 
1970). The latter would also explain both the increase in TSH and decrease in fT3 and T3 
levels. Also, the inhibition of the 5’deiodinase I, in charge of forming T3 from T4 (Bauer et 
al. 2006), would explain the decrease in the T3 levels. Inhibition of iodine uptake might occur 
by the competition of lithium with iodine in, for example, the sodium-iodine symporter, 
which is the way iodine is taken up in the thyroid gland (Eskandari et al. 1997).  
The associations with TTR have, however, not been reported previously. Therefore, if 
confirmed in other studies, the indicated decrease in the TTR levels due to lithium might be a 
novel mechanism of action. Importantly, TTR is one of the proteins responsible for 
transporting T4 in the body and the most abundant T4 transporter in the cerebrospinal fluid 
(Schreiber et al. 1995). Also, TTR is produced in placental trophoblastic cells and is in charge 
of transporting thyroid hormones to the fetus (McKinnon et al. 2005). The decrease in TTR 
concentrations can, thus, result in lower fetal thyroid hormone levels (Darnerud et al. 1996). 
  
5.3.2 Impairment of the maternal calcium homeostasis 
Another common side-effect of lithium medication is the impairment of the calcium 
homeostasis (McKnight et al. 2012). Therefore, we tested whether also environmental 
exposure to lithium might have similar effects in pregnant women (Paper IV). It could, like 
the disruption of thyroid function, be a potential underlying mechanism of the inverse 
association of lithium with fetal size. To elucidate a potential impact of lithium exposure 
through drinking water on the calcium homeostasis, we measured different markers in 
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maternal serum and investigated their association with blood lithium concentrations during 
pregnancy. The selected markers of calcium homeostasis included: serum calcium (total and 
albumin-adjusted), urinary calcium, serum PTH, plasma 25-hydroxivitamin D3 (vitamin D3), 
as well as total phosphorus and magnesium in serum and urine. The correlation between the 
different markers in late pregnancy varied, with the highest between urinary magnesium and 
calcium (rs=0.51), serum magnesium with total serum calcium (rs=0.37), serum phosphorus 
and albumin-adjusted serum calcium (rs=0.22) and PTH and vitamin D3 (rs=0.22). Six women 
had elevated albumin-adjusted serum calcium concentrations, while 58% of the women had 
vitamin D3 concentrations <50 nmol/L and 19%, <30 nmol/L.  
Vitamin D3 concentrations were strongly influenced by the season of sampling, showing the 
lowest concentrations in the winter (June-August) and the highest in the summer (December-
February). One of the main sources of vitamin D3 is UVB radiation which converts 7-
dehydrocholesterol to previtamin D3 in the skin. The study area is located at a latitude 
between -23.31 and -24.35, and although sunlight is present at least 10 hours/day during the 
winter season, the characteristic weather of the Puna region, with cold and very windy 
winters, impose people to use more clothes and to stay indoors longer time, reducing the 
exposure time to sunlight. 
In multivariable-adjusted linear mixed-effects models (longitudinal analyses across 
pregnancy), blood lithium was inversely associated with plasma vitamin D3 concentrations, 
as well as with urinary calcium and magnesium, and positively associated with serum 
magnesium. A 25 μg/L increment in the blood lithium concentrations was associated with an 
odds ratio of 3.5 for having vitamin D3 concentrations <50 nmol/L, and with an odds ratio of 
4.6 for having vitamin D3 concentrations <30 nmol/L. The influence of season of sampling on 
the Vitamin D3 concentrations was independent of that of lithium.  
Low vitamin D concentrations during pregnancy could be unfavorable for the maternal and 
fetal health, as they are associated with an increased risk for preeclampsia and infectious 
diseases during pregnancy in the mother, as well as with impaired fetal programming, low 
birth size, increased risk for inflammatory and immune disorders during infancy and a poorer 
infant bone health (i.e. lower bone mineral density) later in life (Brannon and Picciano 2011; 
Karras et al. 2014).  
There are different mechanisms that could be involved in the inverse associations observed 
between blood lithium and vitamin D3. Due to the lack of associations between lithium and 
PTH, it seems likely that the present associations might be explained by mechanisms 
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occurring outside the parathyroid gland. One possible mechanism is the stimulation of 
fibroblast growth factor 23 (FGF23) by lithium, leading to an enhanced activity of 24-
hydroxylase (CYP24A1) and a consequent increased catabolism of both 25-hydroxyvitamin 
D3 and 1,25-hydroxyvitamin D3 (Fakhri et al. 2014). This would in turn lead to a decrease in 
the urinary excretion of calcium and phosphorus (Brannon and Picciano 2011; Fakhri et al. 
2014). Since we found no clear associations with the levels of phosphorus in our study, this 
hypothesis is not completely compatible with our findings. Nevertheless, findings concerning 
phosphorus have to be interpreted with caution as we measured total phosphorus in serum 
and not only inorganic phosphate.  
Another hypothesis is that the lithium-related decrease of the vitamin D3, urinary calcium and 
urinary magnesium concentrations occurs directly at the kidney level. Impairment of the 
kidney function is a known adverse effect of lithium therapy (McKnight et al. 2012). In fact, 
we found positive associations between blood lithium and urinary albumin. An impaired 
kidney function is associated with lower serum 25-hydroxyvitamin D3 concentrations 
(Damasiewicz et al. 2013; de Boer et al. 2011), although a severe kidney impairment might 
be needed to cause a decrease in the vitamin D3 concentrations. The inverse associations 
between blood lithium and urinary magnesium and calcium could also be explained by such a 
mechanism, considering that their homeostasis is mainly regulated in the kidneys (Blaine et 
al. 2015).  
 
5.3.3 Other potential mechanisms 
It is possible that additional mechanisms are involved in the association of lithium exposure 
with fetal size, but these were not investigated in this thesis. For example, it could be 
speculated that the accumulation of lithium in other endocrine organs could play a role. A 
lithium-related increase in the maternal circulating levels of cortisol, as shown in lithium-
treated patients (Bschor et al. 2002; Platman and Fieve 1968) and in rats (Sugawara et al. 
1988), could lead to a decreased weight, length and head circumference at birth (Duthie and 
Reynolds 2013).  
It is also likely that both mechanisms of lithium toxicity explored in this thesis and other 
suggested mechanisms are complementary, rather than mutually exclusive. More efforts are, 
however, necessary to fully understand the biological processes underlying the potential 
impairment of fetal development due to lithium exposure through drinking water in the 
general population. 
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5.4 METHODOLOGICAL CONSIDERATIONS 
The study in Paper I was based on a few mother-child pairs from San Antonio de los Cobres 
(n=11), in Argentina, and Arica (n=24) and Santiago (n=11), in Chile. We took advantage of 
two previous studies and could clarify that environmental lithium exposure during pregnancy 
results in high fetal exposure, as indicated by the high concentrations in both cord blood and 
the first infant urine in life. In this study, blood, urine and breast milk samples in San Antonio 
de los Cobres were sampled repeatedly, allowing us to see changes over time during the first 
6 months after delivery/birth. A drawback of this study, in addition to the small sample size, 
was the lack of data concerning factors that could affect the transfer of lithium through the 
placenta and mammary gland (e.g. nutrition). 
For Papers II-IV, we recruited a larger mother-child cohort (n=194) covering most of the 
Andean region of the Province of Salta, and sampled different exposure and outcome markers 
repeatedly during and after pregnancy. Indeed, the population-based longitudinal design is a 
strength in addition to the fact that the women in the cohort had wide ranges of exposures. 
Also, all women were nonsmokers and reported very low alcohol consumption, reducing 
such sources of confounding in this cohort. Moreover, in each study, we considered several 
measures of the outcomes, along with the exposure measurements and evaluated potential 
mechanisms and susceptibility factors. In addition, we evaluated other exposures, such as 
cesium, boron and arsenic, also present in the drinking water, and adjusted models 
accordingly. The lower arsenic exposure during the study period (due to the installation of an 
arsenic filter) decreased the possibilities of a combined effect of arsenic with other metals. On 
the contrary, in Paper II, we could not elucidate if the associations found between lithium 
and birth length were a result of lithium exposure exclusively or a consequence of the 
combined exposure to both lithium and boron. Moreover, in Paper III, cesium was also 
inversely associated with fT3 and T3, but not with TSH nor even with TTR, and the 
adjustment of the latter models for cesium did not affect the estimates. 
Studies in Papers II-IV present some limitations. As in all observational studies, our findings 
are just associations and do not infer causality, and we cannot rule out the possibility of 
residual or unmeasured confounding. Therefore, we put much emphasis on the mechanistic 
studies. A drawback of the studies is the lack of measurements of both exposure and outcome 
markers in the first trimester for all women. The main reason for this was the limited 
accessibility to reach the far away villages, especially during the rain period (January-March), 
when the sandy roads often were destroyed, which made it impossible to reach some of the 
study areas. Also, women in the study area might not report, suspect or confirm their 
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pregnancies until the 2nd trimester starts, and thus, the chances of recruiting women in the 
very early gestation were low. Moreover, the wide-spread study area and the study logistics 
did not allow us to collect samples at the same time of the day, and thus variation in the 
biomarkers could not be avoided. 
Due to the discovered contamination of the blood sampling tubes with lithium, serum lithium 
measurements could not be used. This could have made the lithium concentrations 
comparable with those in clinical studies. However, we found a remarkably high correlation 
between the lithium concentrations in plasma (from non-contaminates tubes) and those in 
whole blood, validating the use of the lithium concentrations in whole blood as exposure 
marker. 
Although much effort was put into considering potential confounding factors in the design 
and analyses of each study, remaining or unmeasured confounding could still exist. For 
example, besides the use of psychiatric medication during pregnancy, the maternal mental 
health itself is known to influence the fetal growth (Boden et al. 2012; Grigoriadis et al. 2013; 
Huybrechts et al. 2014). Although none of the women reported any psychiatric diagnoses or 
psychiatric medication in response to our questions about mental health, we cannot 
completely rule out the possibility of underreporting or recall bias.  
The study area is located at high altitude with low atmospheric oxygen concentrations. This 
causes stress on pregnancy and decreases the fertility rate, and it may have certain effect on 
the thyroid function (Kametas et al. 2004; Sarne 2000; Soria et al. 2013; Vitzthum 2013). 
Although these effects seem to be less common among indigenous people living at this high 
altitude for generations than among those with Caucasian influence (Kametas et al. 2004; 
Soria et al. 2013; Vitzthum 2013) and most women in our study reported to belong to 
indigenous communities, mainly Kolla, we did not have specific markers to control for 
ethnicity. Therefore, we cannot rule out the involvement of ethnicity in the findings of 
lithium with maternal and fetal health. 
We did not measure TBG, which increases in early pregnancy and thereby, alters the T3 
levels (Lockitch 1993). Nonetheless, this should have further increased the variation in the T3 
measurements, decreasing the possibilities of finding associations with lithium or cesium. 
Also, DBP and various genetic polymorphisms were not measured, that could have affected 
the vitamin D3 and PTH concentrations, and thereby masked potential associations. 
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Although the sample size in Papers II-IV is much larger than that in Paper I, the cohort is still 
relatively small and we lacked statistical power to perform certain analyses such as 
stratifications by urinary iodine and infant sex, which might have revealed additional 
potential mechanisms, or by categories of exposure (high boron vs. low lithium, etc). Thus, a 
larger sample size in this study could have facilitated the interpretation of the results. 
However, only about 200 women get pregnant every year in the study area and we did recruit 
88% of all pregnant women during October 2012 and December 2013. Also, there is limited 
access and transportation to the surrounding villages, a problem that is still worse in the rain 
period and that challenged the field work of the study. Indeed, the findings of this thesis need 
to be followed-up and hopefully this breakthrough pilot study will stimulate the performance 
of similar studies in larger cohorts and in other populations exposed to lithium through 
drinking water.   
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6 CONCLUSIONS 
Taken together, the results of this thesis provide evidence that elevated exposure to lithium 
through drinking water during pregnancy may adversely affect prenatal development, 
possibly through endocrine disruption. In particular, we found that: 
 
 Lithium was easily transferred through the placenta, giving rise to considerable 
exposure to lithium during fetal life, a potential susceptible window of toxic exposure. 
The transport through the mammary gland was much lower and breast-feeding 
seemed to provide some protection of the infants against lithium exposure.  
 
 Lithium exposure through drinking water during pregnancy was associated with 
shorter birth length. 
 
 Lithium exposure was associated with impaired thyroid function. Maternal blood 
lithium concentrations during pregnancy were positively associated with thyrotropin 
and inversely associated with the active thyroid hormones (fT3 and T3) as well as 
with transthyretin, a transporter of thyroid hormones over e.g. the placenta. 
 
 Lithium exposure was also associated with altered calcium homeostasis. Blood 
lithium concentrations were inversely associated with plasma 25(OH)vitamin D3 and 
with almost 5 times higher odds of having vitamin D3 concentrations <30 nmol/L 
during pregnancy. 
 
If confirmed in other and larger studies, the findings have implications for the public health 
and reinforce the need for thorough screening of lithium concentrations in drinking and 
bottled water and further evaluation of the health effects. 
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7 FUTURE RESEARCH 
Future efforts should focus on the following: 
 
ᴑ Determination of lithium concentrations in drinking water, including bottled water, 
worldwide in order to identify highly exposed individuals and populations. 
ᴑ Follow-up of the children of the presently studied women, to elucidate potential 
effects of the prenatal lithium exposure on infant growth and other potential adverse 
effects, including e.g. impairment of the thyroid and calcium homeostases, as well as 
epigenetic alterations. 
ᴑ Investigation of health effects in the infants due to the continued elevated exposure to 
lithium after weaning. 
ᴑ Investigation of fetal growth and development in relation to lithium exposure in 
several and larger mother-child cohorts, to confirm the findings of the present thesis 
and to facilitate the elaboration of risk assessments for lithium and the decision upon 
health-based guideline values for drinking and bottled water. 
ᴑ Elucidation of other mechanisms underlying the early-life toxicity of lithium. 
ᴑ Identification of susceptibility factors (e.g. polymorphisms in genes related to lithium 
or to vitamin D kinetics, nutritional status, epigenetic mechanisms) that could enhance 
the risk for lithium toxicity. 
ᴑ Consideration of additional outcome markers such as vitamin D-binding protein, 1-
apha-hydroxilase and CYP24A1 activity, and thyroid-binding protein. 
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8 POPULÄRVETENSKAPLIG SAMMANFATTNING 
Litium är en metall som förekommer naturligt i miljön, inklusive dricksvatten i varierande 
halter. Trots att det finns rapporterat att mineralvatten på flaska kan innehålla höga halter 
litium, så analyseras det ytterst sällan i dricksvatten. De få studier som finns visar att 
dricksvatten i visa områden i Österrike, Chile och Argentina kan innehålla upp till ett par 
tusen mikrogram/liter, medan i andra länder, så som Italien, Grekland, Japan och England 
verkar koncentrationerna vara betydligt lägre. Bara Ryssland och Ukraina har nationellt 
gränsvärde för litium i dricksvatten.  
Litium används bland annat för att tillverka batterier och glas men också i medicinering mot 
bipolär (manodepressiv) sjukdom. Litiumbehandlingen har setts kunna ge bieffekter i form av 
påverkad funktion av sköldkörteln och njurarna, samt störa kalciumomsättningen i kroppen. 
Under graviditet är litiumbehandling problematisk och riktlinjen är att så långt som möjligt 
undvika medicinering i början av graviditeten. Man vet från kliniska och experimentella 
studier att litiumbehandling kan påverka fostertillväxten samt orsaka missbildningar. Vi vet 
dock ytterst lite om litiumexponeringen från dricksvatten och om den kan påverka hälsan; det 
finns bara en enda studie som indikerar påverkan på sköldkörtelfunktionen.  
Huvudsyftet med denna avhandling var att undersöka potentiella hälsoeffekter av 
litiumexponering under graviditeten hos kvinnor och deras barn. Vi studerade framför allt 
överföringen av litium till fostret genom moderkakan (placentan) och till det ammade barnet 
genom bröstmjölken, samt påverkan på fostertillväxt. För att utreda eventuella orsaker till en 
antydd fosterpåverkan, så undersökte vi även om litiumexponering under graviditet kan störa 
sköldkörteln och kalciumomsättningen hos mödrarna.   
För fem år sedan rapporterade vår forskargrupp att dricksvattnet i San Antonio de los Cobres, 
ett område i Anderna i norra Argentina, innehöll höga halter litium, förutom höga halter 
arsenik, vilket var känt sedan tidigare. Av denna anledning analyserade vi litium i prover som 
insamlats i detta område under 1996 från en liten mor-barn kohort (11 kvinnor och deras 
barn). Litiumhalterna i navelsträngsblod befanns vara minst lika höga som de i mammas 
blod, vilket indikerar att litium passerar över moderkakan till fostret. Litiumhalterna i 
bröstmjölken var däremot betydligt lägre, vilket tyder på att amningen delvis skyddar barnen 
mot de höga litiumnivåerna i dricksvattnet. 
För att försöka klargöra eventuella effekter av denna exponering på kvinnorna och deras barn, 
rekryterade vi en större mor-barn kohort i samma by samt i ett antal närliggande byar. Vi bjöd 
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in samtliga kvinnor som blev gravida från oktober 2012 till december 2013 att delta. Totalt 
rekryterades 180 kvinnor (88% svarsfrekvens). Vi intervjuade kvinnorna under 1 till 3 
tillfällen under graviditeten och tog blod-, urin- och dricksvattenprover för analys av litium. I 
blod mättes också olika markörer för sköldkörtelfunktion och kalciumomsättning. 
Fosterstorlek mättes med hjälp av ultraljud under graviditeten, samt vikt, längd och 
huvudomfång vid födseln. 
De statistiska analyserna visade att det fanns ett samband mellan en högre litiumexponering 
via dricksvatten och lägre fostertillväxt. På motsvarande sätt fann vi samband mellan 
litiumexponering och förändrade halter av olika sköldkörtelhormoner hos mamman, vilket 
antyder att litium kan störa sköldkörtelfunktionen under graviditet. Vidare fann vi samband 
mellan litiumexponeringen och vitamin D-nivåerna hos mamman som kan betyda att litium 
sänker vitamin D-nivån.  
Sammanfattningsvis så bidrar denna avhandling med ny kunskap om hälsoeffekter av 
litiumexponeringen via dricksvatten. Resultaten visar att en exponering motsvararande 
mindre än 1 procent av den vid litiumbehandling kan påverka fostrets tillväxt negativt. Då 
både sköldkörtelhormoner och hormonet vitamin D är nödvändiga för normal fostertillväxt 
och utveckling, kan det indikerade sambandet mellan litium och dessa hormoner vara en 
möjlig förklaring till påverkan på fostertillväxten. Fynden bör beläggas i större studier i andra 
populationer, men de kan visa sig vara viktiga ur folkhälsosynpunkten och belyser behovet av 
analyser av litium i både dricksvatten och mineralvatten på flaska. 
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9 RESUMEN CIENTÍFICO POPULAR 
Litio es un metal que está presente naturalmente en el ambiente, incluso en el agua potable en 
concentraciones variables. A pesar de que hay reportes que indican que agua embotellada 
puede contener altas concentraciones de litio, este metal es rara vez analizado en el agua 
potable. Los pocos estudios disponibles muestran que el agua potable en ciertas regiones en 
Austria, Chile y Argentina contiene hasta 2 miligramos/litro, mientras que el agua potable en 
países como Italia, Grecia, Japón e Inglaterra parece tener concentraciones mucho más bajas. 
Sólo Rusia y Ucrania tienen valores límite para litio en el agua potable a nivel nacional. 
Litio se utiliza, entre otras cosas, para fabricar baterías y vidrio pero también para tratar la 
enfermedad bipolar. Se ha visto que el tratamiento con litio puede ocasionar efectos adversos 
a la salud tales como afección de la función tiroidea y renal, así como trastornos en el 
metabolismo del calcio. Durante el embarazo, el tratamiento con litio es problemático y guías 
clínicas recomiendan que se evite, tanto como sea posible, la medicación con litio en las 
primeras semanas de embarazo. Se sabe, por estudios clínicos y experimentales, que la 
exposición a litio puede afectar el crecimiento fetal y causar malformaciones congénitas. Sin 
embargo, se sabe muy poco sobre la exposición a litio en el agua potable y sus efectos a la 
salud; existe sólo un estudio y éste indica efectos adversos en la función tiroidea. 
El objetivo principal de esta tesis fue investigar potenciales efectos sobre la salud en mujeres 
y sus hijos debido a la exposición a litio durante el embarazo. Particularmente, estudiamos el 
traspaso de litio al feto a través de la placenta y a los niños a través de la leche materna, así 
como sus efectos en el crecimiento fetal. Para explorar causas potenciales de la afección del 
crecimiento fetal, investigamos también si la exposición a litio puede ocasionar alteraciones 
de la función tiroidea y del metabolismo del calcio en las mujeres embarazadas. 
Hace 5 años, nuestro grupo de investigación reportó que el agua de San Antonio de los 
Cobres, un área en los Andes en el norte Argentino, contiene altas concentraciones de litio, 
además del arsénico que ha sido estudiado previamente. Por esta razón, analizamos litio en 
muestras recolectadas en esta área en 1996, de una cohorte pequeña de madres y niños (11 
mujeres y sus hijos). Las concentraciones de litio en sangre del cordón umbilical fueron 
iguales o más altas que aquellas en sangre materna, lo cual indica que el litio traspasa la 
placenta hacia el feto. Por el contrario, las concentraciones de litio en la leche materna fueron 
mucho más bajas, lo cual sugiere que el amamantamiento exclusivo protege, al menos 
parcialmente, a los niños de la exposición a concentraciones altas de litio en el agua potable. 
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Para tratar de elucidar potenciales efectos sobre la salud debido a esta exposición en las 
mujeres embarazadas y sus hijos, reclutamos una cohorte de madres y niños más grande en la 
misma área y en áreas aledañas. Nosotros invitamos a participar en el estudio a todas las 
mujeres que estuvieron embarazadas desde octubre del 2012 hasta diciembre del 2013. En 
total reclutamos 180 mujeres (tasa de participación del 88%). Entrevistamos a las mujeres de 
1 a 3 veces durante el embarazo y recolectamos muestras de sangre, orina y agua potable en 
las cuales se analizó litio. En sangre se analizó también marcadores de función tiroidea y del 
metabolismo del calcio. El tamaño fetal se midió a través de ultrasonido (ecografía) durante 
el embarazo, y también se midió peso, talla y perímetro cefálico al nacer. 
Los análisis estadísticos mostraron asociaciones entre la exposición a litio a través del agua 
potable y un tamaño fetal más pequeño. De la misma manera, encontramos asociaciones entre 
la exposición a litio y alteración de las concentraciones de las hormonas tiroideas maternas 
durante el embarazo, lo cual indica que el litio puede afectar la función tiroidea durante el 
embarazo. Además, encontramos asociaciones entre la exposición a litio y las 
concentraciones de la vitamina D en las mujeres, lo cual sugiere que el litio parece disminuir 
las concentraciones de la vitamina D.  
En resumen, esta tesis contribuye con conocimiento sobre efectos a la salud de la exposición 
a litio a través del agua potable. Los resultados muestran que la exposición, correspondiente a 
menos del 1% de aquella usada para medicar, podría afectar negativamente el crecimiento 
fetal. La función tiroidea así como la vitamina D son esenciales para el desarrollo y 
crecimiento fetal normal, por lo cual, las asociaciones de litio con estas hormonas podrían ser 
una explicación potencial de la afección del crecimiento fetal. Los hallazgos necesitan ser 
repetidos en cohortes más grandes y en diferentes poblaciones, pero de cualquier manera, los 
resultados son importantes desde el punto de vista de la salud pública y recalcan la necesidad 
de realizar mediciones de litio en agua potable y embotellada.  
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